𐋇 ¦march¦ ¦to¦ 𐋇 ¦a u g ust¦ ¦2020¦
𐋇 ¦cons ul t¦ ¦the¦ ¦high li gh ts¦ ¦from¦ 𐋇 ¦march¦ ¦to¦ 𐋇 ¦a u g ust¦ ¦2020¦
¦ser ies¦ ¦of¦ ¦test¦ ¦t ub es¦ ¦in¦ ¦a¦ ¦d ra w er¦ 
¦3 1¦ 𐋇 ¦a u g ust¦ ¦2020¦ ▁-▁ 𐋇 ¦coronavirus¦ 𐋇 ¦global¦ 𐋇 ¦response¦ :▁ 𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦jo ins¦ ¦the¦  - ¦19¦ 𐋇 ¦vaccine¦ 𐋇 ¦global¦ 𐋇 ¦acc ess¦ 𐋇 ¦facil ity¦
𐋇¦to¦ ¦acc el er ate¦ ¦the¦ ¦development¦ ¦and¦ ¦m an u fa ct ure¦ ¦of¦  - ¦19¦ ¦vaccines¦ ¦for¦ ¦e veryone¦ ¦who¦ ¦needs¦ ¦them¦ ,▁ ¦the¦ 𐋇¦c om mi ssion¦ ¦jo ins¦ ¦the¦ ▁ ‘  - ¦19¦ 𐋇 ¦vaccine¦ 𐋇 ¦global¦ 𐋇 ¦acc ess¦ 𐋇 ¦facil ity¦ ’ .
𐋇 ¦comm is si on er¦ 𐋇 ¦k y r ia k i des¦ ¦sign ing¦ ¦the¦ ¦first¦ ¦contr ac t¦ ¦with¦ ¦the¦ ¦comp an y¦ 𐋇 ¦a st ra 𐋇 z eneca¦
¦2 7¦ 𐋇 ¦a u g ust¦ ¦2020¦ ▁–▁ 𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦f orm ally¦ ¦signs¦ ¦first¦ ¦contr ac t¦ ¦with¦ 𐋇 ¦a st ra 𐋇 z eneca¦
𐋇¦the¦ ¦first¦ ¦contr ac t¦ ¦that¦ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦ne g o ti ated¦ ¦on¦ ¦be h al f¦ ¦of¦ ¦the¦  𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦with¦ ¦a¦ ¦ph ar ma ce ut ical¦ ¦comp an y¦ ¦ent ered¦ ¦into¦ ¦for ce¦ ¦following¦ ¦the¦ ¦f ormal¦ ¦sign at ure¦ ¦between¦ 𐋇 ¦a st ra 𐋇 z eneca¦ ¦and¦ ¦the¦ 𐋇¦c om mi ssion¦ .
𐋇 ¦two¦ ¦m en¦ ¦in¦ ¦a¦ ¦work s ho p¦ 
¦2 5¦ 𐋇 ¦a u g ust¦ ¦2020¦ ▁–▁ 𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦prop o ses¦ ¦to¦ ¦provide¦ ▁ € ¦8 7¦ . ¦3¦ ¦bi ll ion¦ ¦in¦ ¦fi na nc ial¦ ¦support¦ ¦for¦ ¦16¦ 𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦under¦ 
𐋇¦on¦ ¦24¦ ¦and¦ ¦2 5¦ 𐋇 ¦a u g ust¦ ,▁ ¦the¦ 𐋇¦c om mi ssion¦ ¦pres ented¦ ¦prop os als¦ ¦to¦ ¦the¦ 𐋇 ¦cou nc il¦ ¦to¦ ¦gr ant¦ ¦fi na nc ial¦ ¦support¦ ¦of¦ ▁ € ¦8 7¦ .
¦res ear c her¦ ¦in¦ ¦a¦ ¦laboratory¦ 
¦20¦ 𐋇 ¦a u g ust¦ ¦2020¦ ▁–▁ 𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦contin ues¦ ¦exp an ding¦ ¦f ut ure¦ ¦vaccines¦ ¦p ort f o li o¦ ¦through¦ ¦new¦ ¦t al ks¦ ¦with¦ 𐋇¦c u re 𐋇 v a c¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦co nc lu ded¦ ¦ex pl or atory¦ ¦t al ks¦ ¦with¦ 𐋇¦c u re 𐋇 v a c¦ ¦to¦ ¦pote nt ially¦ ¦p ur ch ase¦ ¦a¦ ¦vaccine¦ ¦against¦  - ¦19¦ .
𐋇¦a¦ ¦sc ie nt ist¦ ¦at¦ ¦work¦ ¦in¦ ¦a¦ ¦l ab ¦ 
¦14¦ 𐋇 ¦a u g ust¦ ¦2020¦ ▁–▁ 𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦rea ches¦ ¦first¦ ¦ag r ee ment¦ ¦on¦ ¦a¦ ¦pote ntial¦ ¦vaccine¦ ¦with¦ 𐋇 ¦a st ra 𐋇 z eneca¦
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦rea ched¦ ¦a¦ ¦first¦ ¦ag r ee ment¦ ¦with¦ ¦the¦ ¦ph ar ma ce ut ical¦ ¦comp an y¦ 𐋇 ¦a st ra 𐋇 z eneca¦ ¦to¦ ¦p ur ch ase¦ ¦a¦ ¦pote ntial¦ ¦vaccine¦ ¦against¦  - ¦19¦ .
𐋇 ¦res ear c her¦ ¦wor king¦ ¦on¦ ¦vaccine¦ 
¦13¦ 𐋇 ¦a u g ust¦ ¦2020¦ ▁–▁ 𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦co nc lu des¦ ¦further¦ ¦t al ks¦ ¦to¦ ¦sec ure¦ ¦f ut ure¦ ¦vaccine¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦co nc lu ded¦ ¦ex pl or atory¦ ¦t al ks¦ ¦with¦ 𐋇 ¦jo h ns on¦ ▁ & ▁ 𐋇 ¦jo h ns on¦ ¦to¦ ¦p ur ch ase¦ ¦a¦ ¦pote ntial¦ ¦vaccine¦ ¦against¦ ¦the¦ ¦coronavirus¦ .
𐋇 ¦pres ident¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ ¦said¦ :▁ “ 𐋇 ¦our¦ ¦c itiz ens¦ ' ▁ ¦l ives¦ ¦and¦ ¦our¦ ¦ec on om y¦ ¦need¦ ¦a¦ ¦safe¦ ¦and¦ ¦effective¦ ¦vaccine¦ ¦against¦ ¦the¦ ¦coronavirus¦ .
𐋇 ¦research¦ ¦l ab ¦ 
¦11¦ 𐋇 ¦a u g ust¦ ¦2020¦ ▁-▁ ¦23¦ ¦new¦ ¦research¦ ¦pro j ects¦ ¦to¦ ¦receive¦ ▁ € ¦1 2 8¦ ¦million¦ ¦in¦  ¦f un ding¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦will¦ ¦support¦ ¦23¦ ¦new¦ ¦research¦ ¦pro j ects¦ ¦with¦ ▁ € ¦1 2 8¦ ¦million¦ ¦in¦ ¦response¦ ¦to¦ ¦the¦ ¦coronavirus¦ ¦c ri sis¦ .
𐋇 ¦sa no f i¦ ¦t al ks¦ 
¦3 1¦ 𐋇 ¦j u ly¦ ¦2020¦ ▁–▁ 𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦co nc lu des¦ ¦t al ks¦ ¦to¦ ¦sec ure¦ ¦a¦ ¦f ut ure¦ ¦coronavirus¦ ¦vaccine¦
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦co nc lu ded¦ ¦ex pl or atory¦ ¦t al ks¦ ¦with¦ ¦the¦ ¦ph ar ma ce ut ical¦ ¦comp an y¦ 𐋇 ¦sa no f i¦ ¦to¦ ¦p ur ch ase¦ ¦a¦ ¦pote ntial¦  - ¦19¦ ¦vaccine¦ .
¦sc ie nt ist¦ 
¦2 9¦ 𐋇 ¦j u ly¦ ¦2020¦ ▁-▁ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦sec ures¦  ¦acc ess¦ ¦to¦ 𐋇 ¦rem de si vi r¦ ¦for¦ ¦treatment¦ ¦of¦  - ¦19¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦sign ed¦ ¦a¦ ▁ € ¦6 3¦ ¦million¦ ¦contr ac t¦ ¦with¦ ¦the¦ ¦ph ar ma ce ut ical¦ ¦comp an y¦ 𐋇 ¦g il ead¦ ¦to¦ ¦sec ure¦ ¦treatment¦ ¦doses¦ ¦of¦ 𐋇¦ ve k lu ry¦ ,▁ ¦the¦ ¦br and¦ ¦na me¦ ¦for¦ 𐋇 ¦rem de si vi r¦ .
¦hand s h a ke¦ 
¦2 7¦ 𐋇 ¦j u ly¦ ¦2020¦ ▁-▁ 𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦la un ches¦ ¦call¦ ¦for¦ ¦in n ov ative¦ ¦response¦ ¦and¦ ¦reco ve ry¦ ¦part ne rs hi ps¦ ¦between¦  ¦regi ons¦
𐋇¦to¦ ¦support¦ ¦the¦ ¦coronavirus¦ ¦response¦ ¦and¦ ¦reco ve ry¦ ,▁ ¦and¦ ¦to¦ ¦help¦ ¦regi ons¦ ¦se iz e¦ ¦o pp ort un ities¦ ,▁ ¦the¦ 𐋇¦c om mi ssion¦ ¦is¦ ¦la u nc hing¦ ¦a¦ ¦call¦ ¦for¦ ¦exp r es si ons¦ ¦of¦ ¦inter est¦ ¦for¦ ¦in n ov ation¦ ¦pro j ects¦ ¦between¦ ¦regi ons¦ ,▁ ¦f oc us ing¦ ¦on¦ ¦four¦ ¦the m at ic¦ ¦areas¦ :▁ ¦development¦ ¦of¦ ¦the¦ ¦medical¦ ¦v al ue¦ ¦cha in¦ ;▁ ¦safety¦ ¦and¦ ¦mana ge ment¦ ¦of¦ ¦medical¦ ¦w a st e¦ ;▁ ¦s us ta in able¦ ¦and¦ ¦d ig it al¦ ¦to ur is m¦ ;▁ ¦and¦ ¦the¦ ¦development¦ ¦of¦ ¦h y dr og en¦ ¦techn ol og ies¦ ¦in¦ ¦car b on¦ - ¦in tens ive¦ ¦regi ons¦ .
𐋇 ¦u rs ul a¦ ¦v on¦ ¦ der¦ ¦le y en¦ 
¦23¦ 𐋇 ¦j u ly¦ ¦2020¦ ▁–▁ 𐋇¦c om mi ssion¦ 𐋇 ¦pres ident¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ ¦in¦ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦par l ia ment¦ :▁ “ 𐋇¦t og ether¦ ,▁ ¦we¦ ¦n ow¦ ¦have¦ ¦the¦ ¦ch ance¦ ¦to¦ ¦a ch ie ve¦ ¦so me thing¦ ¦h ist or ic¦ ¦for¦ 𐋇¦e ur ope¦ . ”
𐋇 ¦following¦ ¦an¦ ¦ag r ee ment¦ ¦in¦ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦cou nc il¦ ¦on¦ 𐋇¦e ur ope¦ ’ ¦s¦ 𐋇 ¦reco ve ry¦ 𐋇 ¦pl an¦ ,▁ 𐋇¦c om mi ssion¦ 𐋇 ¦pres ident¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ ¦said¦ ¦in¦ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦par l ia ment¦ :▁ “ 𐋇¦we¦ ¦n ow¦ ¦have¦ ¦ma ss ive¦ ¦and¦ ¦un p r ec ed ented¦ ¦fi na nc ial¦ ¦fi re p ower¦ ▁-▁ € ¦1¦ .
¦b ud g et¦ 
¦ 21¦ 𐋇 ¦j u ly¦ ¦2020¦ ▁–▁ 𐋇 ¦european¦ ¦lea d ers¦ ¦rea ch¦ ¦a¦ ¦de al¦ ¦on¦ ¦the¦ ¦reco ve ry¦ ¦pl an¦ ¦and¦ 𐋇 ¦european¦ ¦long¦ - ¦ter m¦ ¦b ud g et¦ ¦2021¦ - ¦20 2 7¦
𐋇 ¦after¦ ¦4¦ ¦long¦ ¦days¦ ¦and¦ ¦n i gh ts¦ ¦of¦ ¦ne g o ti ations¦ ,▁  ¦lea d ers¦ ¦s uc cess f ul ly¦ ¦ag re ed¦ ¦on¦ ¦the¦ ¦reco ve ry¦ ¦pl an¦ ¦for¦ 𐋇¦e ur ope¦ .
¦testing¦ ¦l ab ¦ ¦ im age¦ 
¦15¦ 𐋇 ¦j u ly¦ ¦2020¦ ▁-▁ 𐋇¦c om mi ssion¦ ¦st re ng th ens¦ ¦pre par ed ness¦ ¦for¦ ¦possible¦ ¦f ut ure¦ ¦coronavirus¦ ¦out b rea ks¦
𐋇 ¦while¦ ¦a im ing¦ ¦to¦ ¦sa ve¦ ¦l ives¦ ¦and¦ ¦to¦ ¦avoid¦ ¦loc k d ow ns¦ ,▁ ¦the¦ 𐋇¦c om mi ssion¦ ¦is¦ ¦s etting¦ ¦out¦ ¦immediate¦ ¦sh ort¦ - ¦ter m¦ ¦measures¦ ¦to¦ ¦st re ng th en¦  ¦health¦ ¦pre par ed ness¦ ¦in¦ ¦case¦ ¦of¦ ¦possible¦ ¦f ut ure¦ ¦coronavirus¦ ¦out b rea ks¦ .
𐋇 ¦u rs ul a¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ ,▁ 𐋇 ¦pres ident¦ ¦of¦ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦sp ee king¦ ¦at¦ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦par l ia ment¦ 
¦8¦ 𐋇 ¦j u ly¦ ¦2020¦ ▁–▁ 𐋇 ¦pres ident¦ 𐋇 ¦u rs ul a¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ :▁ ¦we¦ ¦can¦ ¦e mer ge¦ ¦st ro nger¦ ¦from¦ ¦this¦ ¦c ri sis¦
𐋇¦when¦ ¦add re ss ing¦ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦par l ia ment¦ ¦on¦ ¦the¦ ¦occ as ion¦ ¦of¦ ¦the¦ ¦star t¦ ¦of¦ ¦the¦ 𐋇 ¦g erm an¦ 𐋇 ¦pres ide ncy¦ ¦of¦ ¦the¦ 𐋇 ¦cou nc il¦ ¦of¦ ¦the¦  ,▁ 𐋇 ¦pres ident¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ ¦said¦ :▁ “ 𐋇¦s ol id ar ity¦ ¦me ans¦ ¦that¦ ¦those¦ ¦who¦ ¦need¦ ¦it¦ ,▁ ¦get¦ ¦more¦ ¦support¦ .
¦mo ne y¦ ¦e u ro s¦ 
¦7¦ 𐋇 ¦j u ly¦ ¦2020¦ ▁–▁ 𐋇 ¦su mm er¦ ¦2020¦ 𐋇 ¦ec onomic¦ 𐋇 ¦for ec ast¦ :▁ 𐋇 ¦u ne v en¦ ¦reco ve ry¦ ¦exp ected¦ ¦to¦ ¦ga in¦ ¦tra ction¦ ¦in¦ ¦second¦ ¦h al f¦ ¦of¦ ¦2020¦
𐋇¦d esp ite¦ ¦the¦ ¦sw if t¦ ¦and¦ ¦comp re he ns ive¦ ¦pol ic y¦ ¦response¦ ¦to¦ ¦the¦ ¦corona ¦ - ¦c ri sis¦ ¦at¦ ¦both¦  ¦and¦ ¦national¦ ¦le v els¦ ,▁ ¦the¦ 𐋇 ¦su mm er¦ ¦2020¦ 𐋇 ¦ec onomic¦ 𐋇 ¦for ec ast¦ ¦pro j ects¦ ¦a¦ ¦d ee p¦ ¦rece ssion¦ ¦in¦ ¦the¦  ¦ec on om y¦ ¦this¦ ¦year¦ .
¦1¦ 𐋇 ¦j u ly¦ ¦2020¦ ▁–▁ 𐋇 ¦y ou th¦ 𐋇¦e mploy ment¦ 𐋇 ¦support¦ :▁ ¦a¦ ¦br id ge¦ ¦to¦ ¦j ob s¦ ¦for¦ ¦the¦ ¦ne xt¦ ¦gener ation¦ ¦of¦ 𐋇¦e ur op e ans¦
𐋇¦the¦ ¦coronavirus¦ ¦pandemic¦ ¦has¦ ¦e m ph a si sed¦ ¦the¦ ¦often¦ ¦diffic ul t¦ ¦star t¦ ¦many¦ ¦y ou ng¦ ¦people¦ ¦face¦ ,▁ ¦but¦ ¦y ou ng¦ 𐋇¦e ur op e ans¦ ¦d es er ve¦ ¦the¦ ¦b est¦ ¦o pp ort un ities¦ ¦that¦ 𐋇¦e ur ope¦ ¦can¦ ¦off er¦ .
𐋇 ¦global¦ ¦response¦ ¦ev ent¦ 
¦2 7¦ 𐋇 ¦june¦ ¦2020¦ ▁-▁ 𐋇 ¦coronavirus¦ 𐋇 ¦global¦ 𐋇 ¦response¦ ¦pl ed ging¦ ¦s um mi t¦ ¦m ob i li ses¦ ¦another¦ ▁ € ¦6¦ .
𐋇¦the¦ ▁ ‘ 𐋇 ¦global¦ 𐋇 ¦go al¦ :▁ 𐋇 ¦un ite¦ ¦for¦ ¦our¦ 𐋇¦f ut ure¦ ' ▁ ¦pl ed ging¦ ¦s um mi t¦ ¦or g an i sed¦ ¦by¦ 𐋇 ¦pres ident¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ ¦and¦ 𐋇 ¦global¦ 𐋇¦c itiz en¦ ¦on¦ ¦2 7¦ 𐋇 ¦june¦ ¦m ob i li sed¦ ▁ € ¦6¦ .
𐋇 ¦global¦ ¦response¦ ¦ev ent¦ 
¦26¦ 𐋇 ¦june¦ ¦2020¦ ▁-▁ 𐋇 ¦coronavirus¦ 𐋇 ¦global¦ 𐋇 ¦response¦ :▁ ¦t un e¦ ¦in¦ ¦to¦ ¦s um mi t¦ ¦and¦ ¦concer t¦ ¦on¦ 𐋇¦s at ur day¦ ,▁ ¦2 7¦ 𐋇 ¦june¦ ¦at¦ ¦3 p m¦  .
𐋇¦the¦ ¦global¦ ¦pl ed ging¦ ¦s um mi t¦ ¦and¦ ¦concer t¦ ¦or g an i sed¦ ¦by¦ ¦the¦ 𐋇¦c om mi ssion¦ ¦and¦ 𐋇 ¦global¦ 𐋇¦c itiz en¦ ¦is¦ ¦happ ening¦ ¦this¦ 𐋇¦s at ur day¦ ▁( ¦2 7¦ 𐋇 ¦june¦ ).
𐋇 ¦coronavirus¦ ¦global¦ ¦response¦ 
¦2 2¦ 𐋇 ¦june¦ ¦2020¦ ▁-▁ 𐋇 ¦coronavirus¦ 𐋇 ¦global¦ 𐋇 ¦response¦ :▁ 𐋇¦c om mi ssion¦ ¦an no un ces¦ ¦world¦ ¦lea d ers¦ ’ ▁ ¦s um mi t¦ ¦and¦ ¦concer t¦ ¦ line¦ - ¦up¦ ¦for¦ ¦2 7¦ 𐋇 ¦june¦ ¦pl ed ging¦ ¦ev ent¦
𐋇 ¦ar ti sts¦ ¦have¦ ¦the¦ ¦p ower¦ ¦to¦ ¦i ns p ir e¦ ¦ch ange¦ .
¦1 7¦ 𐋇 ¦june¦ ¦2020¦ ▁–▁   - ¦19¦ ¦vaccines¦ ¦stra te g y¦ ¦un ve il ed¦
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦pres ented¦ ¦a¦ 𐋇 ¦european¦ ¦stra te g y¦ ¦to¦ ¦acc el er ate¦ ¦the¦ ¦development¦ ,▁ ¦m an u fa ct ur ing¦ ¦and¦ ¦dep lo y ment¦ ¦of¦ ¦coronavirus¦ ¦vaccines¦ ¦as¦ ¦it¦ ¦is¦ ¦our¦ ¦b est¦ ¦b et¦ ¦at¦ ¦per ma ne ntly¦ ¦be ating¦ ¦the¦ ¦pandemic¦ ¦within¦ ¦a¦ ¦ti me f ra me¦ ¦of¦ ¦12¦ ¦to¦ ¦18¦ ¦mon ths¦ ,▁ ¦if¦ ¦not¦ ¦ ear li er¦ .
¦reop en¦ ¦eu¦ ¦v is ual¦ 
¦15¦ 𐋇 ¦june¦ ¦2020¦ ▁-▁ ‘ 𐋇 ¦r e¦ - ¦open¦  ’ ▁–▁ ¦a¦ ¦new¦ ¦we b ¦ ¦pl at for m¦ ¦la un ched¦ ¦to¦ ¦sa f ely¦ ¦res u me¦ ¦fre e¦ ¦mo ve ment¦ ¦and¦ ¦to ur is m¦ ¦in¦ ¦the¦ 
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦la un ched¦ ▁ ‘ 𐋇 ¦r e¦ - ¦open¦  ’ ,▁ ¦a¦ ¦we b ¦ ¦pl at for m¦ ¦that¦ ¦conta ins¦ ¦essential¦ ¦information¦ ¦for¦ ¦a¦ ¦safe¦ ¦re la un ch¦ ¦of¦ ¦fre e¦ ¦mo ve ment¦ ¦and¦ ¦to ur is m¦ ¦across¦ 𐋇¦e ur ope¦ ,▁ ¦so¦ ¦that¦ ¦you¦ ¦conf ide ntly¦ ¦can¦ ¦en j o y¦ ¦your¦ ¦up c om ing¦ ¦h ol id ays¦ .
¦m an¦ ¦with¦ ¦mask¦ ¦chec king¦ ¦hi s¦ ¦phone¦ 
¦10¦ 𐋇 ¦june¦ ¦2020¦ ▁–▁  ¦ste ps¦ ¦up¦ ¦a ction¦ ¦to¦ ¦f ight¦ ¦coronavirus¦ ¦disinf orm ation¦
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦and¦ ¦the¦ 𐋇 ¦high¦ 𐋇 ¦rep re se nt ative¦ ¦are¦ ¦ste pping¦ ¦up¦ ¦the¦ ¦f ight¦ ¦against¦ ¦coronavirus¦ ¦disinf orm ation¦ ¦by¦ ¦prop os ing¦ ¦a¦ ¦way¦ ¦for w ard¦ ¦in¦ ¦a¦ 𐋇 ¦jo in t¦ 𐋇 ¦comm un ic ation¦ .
𐋇 ¦int eri or¦ ¦of¦ ¦an¦ ¦in n ov ation¦ ¦l ab ¦ 
¦8¦ 𐋇 ¦june¦ ¦2020¦ ▁–▁ 𐋇¦to¦ ¦f ight¦ ¦the¦ ¦coronavirus¦ ¦and¦ ¦to¦ ¦support¦ ¦the¦ ¦reco ve ry¦ ,▁  ¦g ra nts¦ ▁ € ¦3 1 4¦ ¦million¦ ¦to¦ ¦in n ov ative¦ ¦comp an ies¦
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦announced¦ ¦that¦ ¦it¦ ¦has¦ ¦a w ar ded¦ ¦3 6¦ ¦comp an ies¦ ¦with¦ ¦ne arly¦ ▁ € ¦1 6 6¦ ¦million¦ ,▁ ¦v ia¦ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦in n ov ation¦ 𐋇 ¦cou nc il¦ 𐋇 ¦acc el erat or¦ 𐋇¦p il ot¦ ,▁ ¦will¦ ¦work¦ ¦on¦ ¦p i o ne ering¦ ¦pro j ects¦ :▁ ¦bi o¦ - ¦dec on ta m ination¦ ¦w ip es¦ ,▁ ¦develop ing¦ ¦low¦ - ¦c ost¦ ¦m ass¦ ¦c as u al t y¦ ¦ ventil ation¦ ¦monit or ing¦ ¦sys tems¦ ,▁ ¦and¦ ¦an¦ ¦antibo dy¦ ¦pl at for m¦ ¦to¦ ¦tre at¦ ¦severe¦ ¦cases¦ ¦of¦ ¦infection¦ 
¦4¦ 𐋇 ¦june¦ ¦2020¦ ▁-▁ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦pl ed ges¦ ▁ € ¦3 00¦ ¦million¦ ¦to¦ ¦the¦ 𐋇 ¦vaccine¦ 𐋇 ¦al li ance¦
𐋇¦on¦ ¦4¦ 𐋇 ¦june¦ ,▁ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦announced¦ ¦a¦ ▁ € ¦3 00¦ ¦million¦ ¦pl ed ge¦ ¦to¦ 𐋇 ¦ga v i¦ ,▁ ¦the¦ 𐋇 ¦vaccine¦ 𐋇 ¦al li ance¦ ,▁ ¦for¦ ¦the¦ ¦period¦ ¦2021¦ – ¦20 2 5¦ 
¦3¦ 𐋇 ¦june¦ ¦2020¦ ▁–▁ 𐋇¦c om mi ssion¦ ¦ta k es¦ ¦first¦ ¦ste p¦ ¦t ow ards¦ ¦ad o ption¦ ¦of¦ ¦a¦ 𐋇 ¦ph ar ma ce ut ical¦ 𐋇 ¦stra te g y¦ ¦for¦ 𐋇¦e ur ope¦
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦publ ished¦ ¦a¦ ¦ro a d ma p¦ ¦on¦ ¦the¦ 𐋇 ¦ph ar ma ce ut ical¦ 𐋇 ¦stra te g y¦ ¦for¦ 𐋇¦e ur ope¦ .
¦global¦ ¦response¦ 
¦2 8¦ 𐋇 ¦may¦ ¦2020¦ ▁-▁ 𐋇 ¦coronavirus¦ 𐋇 ¦global¦ 𐋇 ¦response¦ :▁ “ 𐋇 ¦global¦ 𐋇 ¦go al¦ :▁ 𐋇 ¦un ite¦ 𐋇¦for¦ 𐋇 ¦our¦ 𐋇¦f ut ure¦ ” ▁ ¦k ick¦ - ¦off ¦ ¦with¦ ¦support¦ ¦from¦ 𐋇 ¦global¦ 𐋇¦c itiz en¦
𐋇¦the¦ 𐋇 ¦coronavirus¦ 𐋇 ¦global¦ 𐋇 ¦response¦ ¦was¦ ¦k ick¦ - ¦star ted¦ ¦on¦ ¦4¦ 𐋇 ¦may¦ ¦and¦ ¦has¦ ¦so¦ ¦fa r¦ ¦r ai sed¦ ▁ € ¦9¦ , ¦8¦ ¦bi ll ion¦ ¦for¦ ¦univers al¦ ¦acc ess¦ ¦to¦ ¦aff or d able¦ ¦coronavirus¦ ¦vacc ination¦ ,▁ ¦tre at ments¦ ¦and¦ ¦testing¦ .
𐋇 ¦reco ve ry¦ ¦pl an¦ ¦for¦ 𐋇¦e ur ope¦ 
¦2 7¦ 𐋇 ¦may¦ ¦2020¦ ▁-▁ 𐋇¦e ur ope¦ ’ ¦s¦ ¦mo ment¦ :▁ ¦major¦ ▁ € ¦2¦ , ¦4¦ ¦t ri ll ion¦ 𐋇 ¦reco ve ry¦ 𐋇 ¦pl an¦ ¦for¦ 𐋇¦e ur ope¦ ¦un ve il ed¦ ¦to¦ ¦rep ai r¦ ¦and¦ ¦pre p are¦ ¦for¦ ¦the¦ ¦ne xt¦ ¦gener ation¦
𐋇¦to¦ ¦k ick¦ - ¦star t¦ ¦the¦ 𐋇 ¦european¦ ¦reco ve ry¦ ,▁ ¦protect¦ ¦l ives¦ ,▁ ¦li ve li h oo ds¦ ¦and¦ ¦j ob s¦ ,▁ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦is¦ ¦prop os ing¦ ¦a¦ ¦major¦ ▁ € ¦2¦ , ¦4¦ ¦t ri ll ion¦ ¦reco ve ry¦ ¦pl an¦ ¦which¦ ¦is¦ ¦based¦ ¦on¦ ¦using¦ ¦the¦ ¦f ul l¦ ¦pote ntial¦ ¦of¦ ¦a¦ ¦p ow er ful¦ ,▁ ¦mod er n¦ ¦and¦ ¦re v a mp ed¦  ¦b ud g et¦ ¦to¦ ¦de li ver¦ ¦a¦ ¦more¦ ¦s us ta in able¦ ,▁ ¦d ig it al¦ ,▁ ¦inclu s ive¦ ¦and¦ ¦f ai r¦ 𐋇¦e ur ope¦ 
¦26¦ 𐋇 ¦may¦ ¦2020¦ ▁-▁ 𐋇 ¦coronavirus¦ ¦s ol id ar ity¦ :▁  𐋇 ¦ind u st ry¦ ¦ste ps¦ ¦in¦ ¦to¦ ¦protect¦ 𐋇 ¦european¦ ¦c itiz ens¦
𐋇 ¦european¦ ¦comp an ies¦ ¦have¦ ¦sh own¦ ¦ext ra or d in ary¦ ¦s ol id ar ity¦ ¦in¦ ¦this¦ ¦c ri sis¦ .
 ¦se m es ter¦ 
¦20¦ 𐋇 ¦may¦ ¦2020¦ ▁-▁ 𐋇 ¦european¦ 𐋇 ¦se m es ter¦ 𐋇 ¦sp r ing¦ 𐋇¦p ac k age¦ :▁ 𐋇 ¦recomm end ations¦ ¦for¦ ¦a¦ ¦co or d in ated¦ ¦response¦ ¦to¦ ¦the¦ ¦coronavirus¦ ¦pandemic¦
𐋇¦on¦ ¦20¦ 𐋇 ¦may¦ ,▁ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦prop osed¦ ¦country¦ - ¦specific¦ ¦recomm end ations¦ ¦for¦ ¦all¦  𐋇 ¦me mbers¦ 𐋇 ¦states¦ ¦and¦ ¦the¦ 𐋇 ¦united¦ 𐋇 ¦ki ng d om¦ ,▁ ¦based¦ ¦up on¦ ¦the¦ 𐋇¦c om mi ssion¦ ’ ¦s¦ ¦gr ow th¦ ¦stra te g y¦ ,▁ ¦which¦ ¦pro mo tes¦ ¦comp e ti tive¦ ¦su st ai na bility¦ ¦to¦ ¦bu i ld¦ ¦an¦ ¦ec on om y¦ ¦that¦ ¦wor ks¦ ¦for¦ ¦people¦ ¦and¦ ¦the¦ ¦pl an et¦ .
¦res ear c her¦ ¦covid¦ - ¦19¦ 
¦19¦ 𐋇 ¦may¦ ¦2020¦ ▁–▁ 𐋇 ¦coronavirus¦ ¦research¦ ¦ bo os ted¦ ¦by¦ ▁ € ¦1 2 2¦ ¦million¦ ¦of¦ ¦ad di tional¦ ¦f un ding¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦m ob i li sed¦ ¦another¦ ▁ € ¦1 2 2¦ ¦million¦ ¦from¦ ¦its¦ ¦research¦ ¦and¦ ¦in n ov ation¦ ¦pr ogra m me¦ ,▁ 𐋇¦h or iz on¦ ¦2020¦ ,▁ ¦for¦ ¦ ur ge ntly¦ ¦nee ded¦ ¦research¦ ¦into¦ ¦the¦ ¦coronavirus¦ .
¦air p ort¦ 
¦13¦ 𐋇 ¦may¦ ¦2020¦ ▁–▁ 𐋇 ¦sa f ely¦ ¦res um ing¦ ¦travel¦ ¦and¦ ¦re b oo ting¦ 𐋇¦e ur ope¦ ’ ¦s¦ ¦to ur is m¦ :▁ 𐋇¦c om mi ssion¦ ¦ta k es¦ ¦a ction¦
𐋇¦to¦ ¦all ow¦ ¦people¦ ¦to¦ ¦take¦ ¦h ol id ays¦ ¦and¦ ¦c at ch¦ ¦up¦ ¦with¦ ¦their¦ ¦f ri ends¦ ¦and¦ ¦fa m il ies¦ ,▁ ¦to¦ ¦l et¦ ¦to ur is m¦ ¦b us in es ses¦ ¦reop en¦ ¦after¦ ¦mon ths¦ ¦of¦ ¦being¦ ¦loc ked¦ ¦down¦ ,▁ ¦and¦ ¦to¦ ¦help¦ 𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦help¦ ¦g rad ually¦ ¦l if t¦ ¦travel¦ ¦restrictions¦ ¦while¦ ¦resp ecting¦ ¦the¦ ¦ne cess ary¦ ¦health¦ ¦pr ec a u tions¦ ,▁ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦pres ented¦ ¦a¦ ¦s et¦ ¦of¦ ¦gu id el ines¦ ¦and¦ ¦recomm end ations¦ ¦for¦ ¦tou ri sts¦ ,▁ ¦tra ve ll ers¦ ¦and¦ ¦b us in es ses¦ .
𐋇 ¦medical¦ ¦research¦ 
¦12¦ 𐋇 ¦may¦ ¦2020¦ - ▁ € ¦1 1 7¦ ¦million¦ ¦gr an ted¦ ¦for¦ 𐋇 ¦coronavirus¦ ¦tre at ments¦ ¦and¦ ¦diagn o st ics¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦s el ected¦ ¦8¦ ¦large¦ - ¦sc a le¦ ¦research¦ ¦pro j ects¦ ¦ ai med¦ ¦at¦ ¦develop ing¦ ¦tre at ments¦ ¦and¦ ¦diagn o st ics¦ ¦for¦ ¦the¦ ¦coronavirus¦ ,▁ ¦in¦ ¦a¦ ¦f ast¦ - ¦tr ack¦ ¦call¦ ¦for¦ ¦prop os als¦ ¦la un ched¦ ¦in¦ 𐋇 ¦march¦ ¦by¦ ¦the¦ 𐋇 ¦in n ov ative¦ 𐋇 ¦medic ines¦ 𐋇 ¦in i ti ative¦ ▁(  ),▁ ¦a¦ ¦public¦ - ¦priv ate¦ ¦part ne rs hi p¦ .
¦masks¦ ¦de li ve ry¦ 
¦11¦ 𐋇 ¦may¦ ¦2020¦ ▁–▁ 𐋇 ¦european¦ ¦s ol id ar ity¦ ¦in¦ ¦a ction¦ ▁–▁  ¦masks¦ ¦del iv ered¦ ¦to¦ 𐋇¦n or th¦ 𐋇¦m ac ed on ia¦ ¦and¦ 𐋇 ¦mon te ne g r o¦
𐋇 ¦following¦ ¦prev ious¦ ¦de li ver ies¦ ¦to¦ 𐋇 ¦italy¦ ,▁ 𐋇¦s pa in¦ ¦and¦ 𐋇¦c ro at ia¦ ,▁ ¦ad di tional¦ ¦b at ches¦ ¦of¦ ¦masks¦ ¦are¦ ¦being¦ ¦del iv ered¦ ¦to¦ 𐋇¦n or th¦ 𐋇¦m ac ed on ia¦ ¦and¦ 𐋇 ¦mon te ne g r o¦ ¦v ia¦  ▁–▁ ¦the¦ ¦common¦ 𐋇 ¦european¦ ¦res er ve¦ ¦of¦ ¦medical¦ ¦equipment¦ ¦to¦ ¦help¦ ¦countries¦ ¦affected¦ ¦by¦ ¦the¦ ¦coronavirus¦ ¦outbreak¦ .
𐋇 ¦masks¦ ¦de li ve ry¦ 
¦8¦ 𐋇 ¦may¦ ¦2020¦ ▁–▁ 𐋇 ¦european¦ ¦s ol id ar ity¦ ¦in¦ ¦a ction¦ ▁–▁ ¦the¦ 𐋇¦c om mi ssion¦ ¦del iv ers¦ ¦first¦ ¦b at ch¦ ¦of¦ ¦1¦ . ¦5¦ ¦million¦ ¦masks¦ ¦to¦ ¦support¦  ¦health¦ ¦workers¦
𐋇¦a¦ ¦first¦ ¦b at ch¦ ¦of¦ ¦1¦ , ¦5¦ ¦million¦ ¦medical¦ ¦masks¦ ¦is¦ ¦being¦ ¦del iv ered¦ ¦to¦ ¦1 7¦ 𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦and¦ ¦the¦  ¦to¦ ¦protect¦ ¦healthcare¦ ¦workers¦ ¦against¦ ¦coronavirus¦ .
¦high l ight¦ 
¦7¦ 𐋇 ¦may¦ ¦2020¦ ▁–▁ 𐋇¦c om mi ssion¦ ¦h el ps¦ 𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦ad dr ess¦ ¦the¦ ¦sh or ta ges¦ ¦of¦ ¦health¦ ¦workers¦ ¦sp e ed¦ ¦up¦ ¦the¦ ¦reco gn ition¦ ¦of¦ ¦health¦ ¦workers¦ ’ ▁ ¦pro f es si on al¦ ¦qu al if ications¦
𐋇¦to¦ ¦help¦ ¦ad dr ess¦ ¦the¦ ¦sh or ta ges¦ ¦of¦ ¦health¦ ¦workers¦ ,▁ ¦the¦ 𐋇¦c om mi ssion¦ ¦issued¦ ¦a¦ 𐋇 ¦comm un ic ation¦ ¦which¦ ¦provid es¦ ¦gu id ance¦ ¦for¦ 𐋇 ¦me mber¦ 𐋇 ¦states¦ .
𐋇 ¦ma p¦ ¦of¦ ¦sp r ing¦ ¦ec onomic¦ ¦for ec ast¦ 
¦6¦ 𐋇 ¦may¦ ¦2020¦ ▁–▁ 𐋇 ¦sp r ing¦ ¦2020¦ 𐋇 ¦ec onomic¦ 𐋇 ¦for ec ast¦ ▁–▁ ¦rece ssion¦ ¦and¦ ¦reco ve ry¦
𐋇¦d esp ite¦ ¦the¦ ¦sw if t¦ ¦and¦ ¦dec is ive¦  ¦and¦ ¦national¦ ¦resp on ses¦ ,▁ ¦the¦  ¦ec on om y¦ ¦will¦ ¦exp eri ence¦ ¦a¦ ¦rece ssion¦ ¦this¦ ¦year¦ ¦as¦ ¦the¦ ¦coronavirus¦ ¦pandemic¦ ¦ca me¦ ¦as¦ ¦a¦ ¦major¦ ¦ec onomic¦ ¦sh oc k¦ .
𐋇¦p i ct ure¦ ¦of¦ 𐋇 ¦pres ident¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ 
¦4¦ 𐋇 ¦may¦ ¦2020¦ ▁–▁ 𐋇 ¦coronavirus¦ 𐋇 ¦global¦ 𐋇 ¦response¦ :▁ € ¦7¦ , ¦4¦ ¦bi ll ion¦ ¦r ai sed¦ ¦from¦ ¦d on ors¦ ¦worldwide¦ ¦for¦ ¦univers al¦ ¦acc ess¦ ¦to¦ ¦vaccines¦ ▁
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦reg ist ered¦ ▁ € ¦7¦ .
𐋇¦p i ct ure¦ ¦of¦ ¦the¦ ¦b an n er¦ ¦on¦ ¦the¦ 𐋇¦b er la y m on t¦ ¦bu il ding¦ 
¦2¦ 𐋇 ¦may¦ ¦2020¦ ▁–▁ 𐋇¦f in al¦ ¦cou nt d own¦ :▁ 𐋇 ¦coronavirus¦ 𐋇 ¦global¦ 𐋇 ¦response¦ ¦pl ed ging¦ ¦m ara th on¦ ¦star ts¦ ¦on¦ 𐋇 ¦mon day¦ ¦4¦ 𐋇 ¦may¦
𐋇 ¦with¦ ¦the¦ 𐋇 ¦coronavirus¦ 𐋇 ¦global¦ 𐋇 ¦response¦ ,▁ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦un ion¦ ¦is¦ ¦j oi ning¦ ¦for ces¦ ¦with¦ ¦global¦ ¦part n ers¦ ¦to¦ ¦k ick¦ - ¦star t¦ ¦a¦ ¦worldwide¦ ¦pl ed ging¦ ¦eff ort¦ ¦to¦ ¦develop ¦ ¦tre at ments¦ ,▁ ¦vaccines¦ ¦and¦ ¦diagn o st ics¦ .
𐋇 ¦pres ident¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ ¦said¦ :▁ “ 𐋇¦on¦ ¦4¦ 𐋇 ¦may¦ ,▁ ¦we¦ ¦w ant¦ ¦to¦ ¦br ing¦ ¦the¦ ¦world¦ ¦t og ether¦ ¦to¦ ¦de li ver¦ ¦on¦ ¦pre vention¦ ,▁ ¦diagn o st ics¦ ¦and¦ ¦tre at ments¦ ¦against¦ ¦coronavirus¦ .
¦online¦ ¦cons um ers¦ 
¦30¦ 𐋇 ¦april¦ ¦2020¦ ▁–▁ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦do ub les¦ ¦down¦ ¦on¦ ¦prev ening¦ ¦sc a ms¦ ¦and¦ ¦prot ecting¦ ¦cons um ers¦
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦is¦ ¦comm it ted¦ ¦to¦ ¦prot ecting¦ ¦cons um ers¦ ¦online¦ ▁–▁ ¦especially¦ ¦during¦ ¦the¦ ¦coronavirus¦ ¦pandemic¦ ¦where¦ ¦some¦ ¦r og ue¦ ¦a ctors¦ ¦are¦ ¦pro mo ting¦ ¦f al se¦ ¦cl ai ms¦ ¦or¦ ¦sc am¦ ¦produc ts¦ .
¦we st er n¦ ¦b al k ans¦ ¦a id¦ 
¦2 9¦ 𐋇 ¦april¦ ¦2020¦ ▁–▁ 𐋇¦t ac k l ing¦ ¦the¦ ¦coronavirus¦ ¦c ri sis¦ :▁ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦ste ps¦ ¦up¦ ¦its¦ ¦support¦ ¦to¦ ¦the¦ 𐋇 ¦we st er n¦ 𐋇¦b al k ans¦
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦announced¦ ¦over¦ ▁ € ¦3¦ .
𐋇 ¦v al di s¦ 𐋇 ¦do mb r ov s k i s¦ 𐋇 ¦pr ess¦ 𐋇 ¦conf er ence¦ 
¦2 8¦ 𐋇 ¦april¦ ¦2020¦ ▁–▁ 𐋇¦b an king¦ ¦p ac k age¦ :▁ ¦supp orting¦ ¦hou se h ol ds¦ ¦and¦ ¦b us in es ses¦ ¦in¦ ¦the¦ 
𐋇¦to¦ ¦e ns ure¦ ¦that¦ ¦b an ks¦ ¦can¦ ¦continue¦ ¦to¦ ¦l end¦ ¦mo ne y¦ ,▁ ¦support¦ ¦the¦ ¦ec on om y¦ ¦and¦ ¦help¦ ¦m it ig ate¦ ¦the¦ ¦ec onomic¦ ¦impac ts¦ ¦of¦ ¦the¦ 𐋇 ¦coronavirus¦ ,▁ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦ad op ted¦ ¦a¦ ¦b an king¦ ¦p ac k age¦ .
¦global¦ ¦s um mi t¦ 
¦2 7¦ 𐋇 ¦april¦ ¦2020¦ ▁-▁  ¦la un ches¦ ¦global¦ ¦pl ed ging¦ ¦eff ort¦ ¦with¦ ¦part n ers¦
𐋇¦to¦ ¦develop ¦ ¦and¦ ¦dep lo y¦ ¦safe¦ ,▁ ¦effective¦ ¦and¦ ¦aff or d able¦ ¦diagn o st ics¦ ,▁ ¦ ther ap e ut ics¦ ¦and¦ ¦vaccines¦ ¦against¦ ¦coronavirus¦ ,▁ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦un ion¦ ¦is¦ ¦j oi ning¦ ¦for ces¦ ¦with¦ ¦global¦ ¦part n ers¦ ¦to¦ ¦k ick¦ - ¦star t¦ ¦a¦ ¦pl ed ging¦ ¦eff ort¦ ▁–▁ ¦the¦ 𐋇 ¦coronavirus¦ 𐋇 ¦global¦ 𐋇 ¦response¦ ▁–▁ ¦star ting¦ ¦on¦ ¦4¦ 𐋇 ¦may¦ ¦2020¦ .
¦u rs ul a¦ ¦v on¦ ¦ der¦ ¦le y en¦ ¦v ide o¦ ¦conf er ence¦ 
¦24¦ 𐋇 ¦april¦ ¦2020¦ ▁–▁ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦to¦ ¦sh ap e¦ ¦a¦ ¦common¦ ¦reco ve ry¦ ¦pl an¦ ¦with¦ ¦a¦ ¦re v a mp ed¦  ¦long¦ - ¦ter m¦ ¦b ud g et¦ ¦at¦ ¦its¦ ¦h ear t¦ ▁
𐋇 ¦european¦ ¦lea d ers¦ ¦t as ked¦ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦with¦ ¦sh ap ing¦ ¦a¦ ¦coll ective¦ ¦response¦ ¦to¦ ¦the¦ ¦c ri sis¦ ¦following¦ ¦a¦ ¦v ide oc on f er ence¦ ¦on¦ ¦23¦ 𐋇 ¦april¦ .
¦ag r ic ol t ure¦ ¦pr ogra mm es¦ 
¦23¦ 𐋇 ¦april¦ ¦2020¦ ▁-▁ 𐋇 ¦ex cep tional¦ ¦measures¦ ¦to¦ ¦support¦ ¦the¦ ¦ag r ic ult ural¦ ¦food¦ ¦s ector¦
𐋇¦to¦ ¦sw if t ly¦ ¦support¦ ¦ag r ic ult ural¦ ¦s ector¦ ¦and¦ ¦food¦ ¦mark ets¦ ¦following¦ ¦the¦ ¦outbreak¦ ¦of¦ ¦the¦ ¦coronavirus¦ ,▁ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦prop osed¦ ¦ex cep tional¦ ¦measures¦ .
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦prop o ses¦ ¦to¦ ¦gr ant¦ ¦priv ate¦ ¦st or age¦ ¦a id¦ ¦for¦ ¦d ai ry¦ ¦and¦ ¦me at¦ ¦produc ts¦ ,▁ ¦f le xi bility¦ ¦in¦ ¦the¦ ¦imp le me nt ation¦ ¦of¦ ¦mark et¦ ¦support¦ ¦pr ogra mm es¦ ¦to¦ ¦ref oc us¦ ¦f un ding¦ ¦pri or ities¦ ,▁ ¦and¦ ¦ex cep tional¦ ¦d er og ation¦ ¦from¦  ¦comp et ition¦ ¦ ru les¦ ¦to¦ ¦st ab il ise¦ ¦the¦ ¦mark ets¦ ¦in¦ ¦different¦ ¦se ctors¦ .
 ¦f la g s¦ 
¦2 2¦ 𐋇 ¦april¦ ¦2020¦ ▁-▁ € ¦3¦ ¦bi ll ion¦ ¦fi na nc ial¦ ¦ass ist ance¦ ¦p ac k age¦ ¦for¦ ¦t en¦ ¦ne i gh bo ur ing¦ ¦countries¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦prop osed¦ ¦a¦ ▁ € ¦3¦ ¦bi ll ion¦ ¦m ac r o¦ - ¦fi na nc ial¦ ¦ass ist ance¦ ¦p ac k age¦ ¦to¦ ¦t en¦ ¦en l ar ge ment¦ ¦and¦ ¦ne i gh bo ur h ood¦ ¦part n ers¦ ¦with¦ ¦the¦ ¦ ai m¦ ¦to¦ ¦limi t¦ ¦the¦ ¦ec onomic¦ ¦f al lo ut¦ ¦of¦ ¦the¦ ¦coronavirus¦ ¦c ri sis¦ ¦in¦ ¦part n er¦ ¦countries¦ .
𐋇¦ im age¦ ¦of¦ ¦hands¦ ¦w earing¦ ¦g lo ves¦ 
¦ 21¦ 𐋇 ¦april¦ ¦2020¦ ▁-▁  ¦m ob i li ses¦ ¦support¦ ¦for¦ 𐋇 ¦italy¦ ,▁ 𐋇¦c ro at ia¦ ¦and¦ ¦ne i gh bo ur ing¦ ¦countries¦
𐋇¦the¦  ¦co or d in ates¦ ¦and¦ ¦c o¦ - ¦f in an ces¦ ¦the¦ ¦de li ve ry¦ ¦of¦ ¦a id¦ ¦sh ip ments¦ ¦in¦ ¦the¦  ¦and¦ ¦in¦ ¦ne i gh bo ur ing¦ ¦countries¦ ,▁ ¦after¦ ¦re qu e sts¦ ¦for¦ ¦ass ist ance¦ ¦v ia¦ ¦the¦  𐋇¦c iv il¦ 𐋇 ¦prote ction¦ 𐋇 ¦me ch an is m¦ ¦in¦ ¦the¦ ¦f ight¦ ¦against¦ ¦the¦ ¦coronavirus¦ ¦pandemic¦ .
𐋇¦ im age¦ ¦of¦ ¦a¦ ¦ser ver¦ ¦ro om¦ 
¦20¦ 𐋇 ¦april¦ ¦2020¦ ▁–▁ 𐋇 ¦coronavirus¦ :▁ 𐋇 ¦new¦ ¦data¦ ¦sh ar ing¦ ¦pl at for m¦ ¦for¦ ¦res ear ch ers¦
𐋇 ¦an¦   - ¦19¦ 𐋇 ¦data¦ 𐋇 ¦pl at for m¦ ¦has¦ ¦been¦ ¦ es ta bl ished¦ ¦by¦ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦and¦ ¦part n ers¦ ¦to¦ ¦rap id ly¦ ¦coll ect¦ ¦and¦ ¦share¦ ¦comp re he ns ive¦ ¦coronavirus¦ ¦research¦ ¦data¦ ,▁ ¦such¦ ¦as¦  ¦se qu en ces¦ ,▁ ¦protein¦ ¦st ru ct ures¦ ,▁ ¦data¦ ¦from¦ ¦pr e¦ - ¦clinical¦ ¦research¦ ¦and¦ ¦clinical¦ ¦trials¦ ,▁ ¦as¦ ¦well¦ ¦as¦ ¦e p ide mi ological¦ ¦data¦ ,▁ ¦to¦ ¦ad v ance¦ ¦research¦ ¦eff orts¦ .
¦p as se nger¦ ¦in¦ ¦an¦ ¦air p ort¦ 
¦1 7¦ 𐋇 ¦april¦ ¦2020¦ ▁-▁ 𐋇 ¦over¦ ¦5 00¦ , ¦000¦  ¦c itiz ens¦ ¦br ou gh t¦ ¦home¦
𐋇¦the¦  ¦has¦ ¦mana ged¦ ¦to¦ ¦br ing¦ ¦home¦ ¦over¦ ¦h al f¦ ¦a¦ ¦million¦ ¦c itiz ens¦ ¦affected¦ ¦by¦ ¦coronavirus¦ ¦travel¦ ¦restrictions¦ ¦by¦ ¦f un ding¦ ¦rep at ri ation¦ ¦f li gh ts¦ ¦and¦ ¦c arr ying¦ ¦out¦ ¦int en se¦ ¦cons ular¦ ¦co op er ation¦ .
¦u rs ul a¦ ¦v on¦ ¦ der¦ ¦le y en¦ ¦pr ess¦ ¦conf er ence¦ 
¦16¦ 𐋇 ¦april¦ ▁–▁ ¦2020¦ ▁–▁ 𐋇 ¦pres ident¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ :▁ “ 𐋇¦the¦ 𐋇 ¦european¦ ¦b ud g et¦ ¦will¦ ¦be¦ ¦the¦ ¦mo ther s hi p¦ ¦of¦ 𐋇¦e ur ope¦ ’ ¦s¦ ¦reco ve ry¦ ”
𐋇¦d esp ite¦ 𐋇¦e ur ope¦ ’ ¦s¦ ¦coll ective¦ ¦response¦ ¦being¦ ¦well¦ ¦a bo ve¦ ▁ € ¦3¦ ¦t ri ll ion¦ ▁–▁ ¦the¦ ¦most¦ ¦imp re ss ive¦ ¦response¦ ¦in¦ ¦the¦ ¦world¦ ▁-▁ ¦more¦ ¦is¦ ¦nee ded¦ ,▁ 𐋇 ¦pres ident¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ ¦said¦ ¦at¦ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦par l ia ment¦ .
¦wom an¦ ¦h ol ding¦ ¦ her¦ ¦phone¦ 
¦16¦ 𐋇 ¦april¦ ▁–▁ ¦2020¦ ▁–▁ 𐋇¦a¦ 𐋇 ¦european¦ ¦appro a ch¦ ¦to¦ ¦trac ing¦ ¦app s¦ ▁–▁ ¦comp le tely¦ ¦v o lu nt ary¦ ¦and¦ ¦f ul ly¦ ¦resp ecting¦ ¦priv acy¦
𐋇¦to¦ ¦ es ta bl ish¦ ¦v o lu nt ary¦ ¦contact¦ ¦trac ing¦ ¦and¦ ¦w ar ning¦ ¦sys tems¦ ¦that¦ ¦f ul ly¦ ¦resp ect¦ ¦priv acy¦ ,▁ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦p ut¦ ¦for w ard¦ ¦a¦ ¦to ol bo x¦ ¦and¦ ¦gu id el ines¦ .
¦ch ar les¦ ¦mi che l¦ ¦and¦ ¦u rs ul a¦ ¦v on¦ ¦ der¦ ¦le y en¦ 
¦15¦ 𐋇 ¦april¦ ¦2020¦ ▁–▁ 𐋇¦a¦ 𐋇 ¦european¦ ¦ro a d ma p¦ ¦to¦ ¦l if ting¦ ¦conta in ment¦ ¦measures¦
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ,▁ ¦in¦ ¦co op er ation¦ ¦with¦ ¦the¦ 𐋇 ¦pres ident¦ ¦of¦ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦cou nc il¦ ¦p ut¦ ¦for w ard¦ ¦a¦ ¦ro a d ma p¦ ,▁ ¦recomm end ations¦ ¦and¦ ¦k e y¦ ¦pri nc ip les¦ ¦to¦ ¦l if ting¦ ¦the¦ ¦conta in ment¦ ¦measures¦ .
𐋇 ¦prot ective¦ ¦medical¦ ¦equipment¦ 
¦14¦ 𐋇 ¦april¦ ¦2020¦ ▁–▁ € ¦2¦ , ¦7¦ ¦bi ll ion¦ ¦from¦ ¦the¦  ¦b ud g et¦ ¦to¦ ¦support¦ ¦the¦ ¦healthcare¦ ¦s ector¦
𐋇¦to¦ ¦dir ect ly¦ ¦support¦ ¦healthcare¦ ¦sys tems¦ ¦in¦  ¦countries¦ ,▁ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦prop osed¦ ¦to¦ ¦activ ate¦ ¦the¦  ’ ¦s¦ 𐋇 ¦emergency¦ 𐋇 ¦support¦ 𐋇 ¦inst ru ment¦ ▁–▁ ¦a¦ ¦me as ure¦ ¦that¦ ¦that¦ 𐋇 ¦cou nc il¦ ¦qu ick ly¦ ¦appr oved¦ ¦on¦ ¦14¦ 𐋇 ¦april¦ .
¦p i lls¦ 
¦8¦ 𐋇 ¦april¦ ¦2020¦ ▁–▁ € ¦15¦ . ¦6¦ ¦bi ll ion¦ ¦for¦ ¦global¦  ¦coronavirus¦ ¦response¦ ;▁  ¦ca lls¦ ¦on¦ 𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦to¦ ¦e ns ure¦ ¦a v ai la bility¦ ¦of¦ ¦medic ines¦
𐋇¦to¦ ¦f ight¦ ¦the¦ ¦coronavirus¦ ¦across¦ ¦the¦ ¦gl ob e¦ ,▁ ¦the¦  ¦will¦ ¦support¦ ¦the¦ ¦public¦ ¦health¦ ¦and¦ ¦ad dr ess¦ ¦the¦ ¦h um an i ta ri an¦ ¦and¦ ¦s an it ary¦ ¦needs¦ ¦of¦ ¦part n er¦ ¦countries¦ ¦across¦ ¦the¦ ¦gl ob e¦ ¦by¦ ¦provid ing¦ ¦fi na nc ial¦ ¦ass ist ance¦ ¦of¦ ¦more¦ ¦than¦ ▁ € ¦15¦ .
¦coronavirus¦ ¦medical¦ ¦uni t¦ 
¦0 7¦ 𐋇 ¦april¦ ¦2020¦ ▁-▁  𐋇 ¦medical¦ 𐋇 ¦cor ps¦ ¦dep lo y ed¦ ¦to¦ 𐋇 ¦italy¦
𐋇 ¦to day¦ ,▁ ¦the¦  𐋇 ¦medical¦ 𐋇 ¦cor ps¦ ¦co or d in ated¦ ¦by¦ ¦the¦  𐋇 ¦emergency¦ 𐋇 ¦response¦ 𐋇 ¦co or d ination¦ 𐋇 ¦centre¦ ¦dis p at ched¦ ¦a¦ ¦team¦ ¦of¦ 𐋇 ¦european¦ ¦do ctors¦ ¦and¦ ¦n ur ses¦ ¦from¦ 𐋇 ¦r om an ia¦ ¦and¦ 𐋇¦n or w ay¦ ¦to¦ 𐋇¦b er g a m o¦ .
𐋇 ¦fi na nc ial¦ ¦a id¦ ¦coronavirus¦ 
¦0 6¦ 𐋇 ¦april¦ ¦2020¦ ▁–▁ € ¦8¦ ¦bi ll ion¦ ¦to¦ ¦support¦ ¦some¦ ¦100¦ , ¦000¦ 𐋇 ¦european¦ ¦b us in es ses¦
𐋇¦f un ding¦ ¦to¦ ¦support¦ ¦and¦ ¦provide¦ ¦rel ief¦ ¦to¦ ¦some¦ ¦100¦ , ¦000¦ ¦b us in es ses¦ ¦hi t¦ ¦by¦ ¦the¦ ¦ec onomic¦ ¦con se qu en ces¦ ¦of¦ ¦the¦ 𐋇 ¦coronavirus¦ ¦will¦ ¦be¦ ¦available¦ ¦in¦ 𐋇 ¦april¦ ¦as¦ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦and¦ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦in ve st ment¦ 𐋇¦f un d¦ ¦un l oc k¦ ▁ € ¦8¦ ¦bi ll ion¦ ¦from¦ ¦th an ks¦ ¦to¦ ¦the¦ 𐋇 ¦european¦ 𐋇¦f un d¦ ¦for¦ 𐋇 ¦stra te g ic¦ 𐋇 ¦in ve st ments¦ .
¦workers¦ ¦produc ing¦ ¦masks¦ 
¦0 3¦ 𐋇 ¦april¦ ¦2020¦ ▁–▁ 𐋇 ¦po st p o ning¦ ¦regul ation¦ ¦for¦ ¦medical¦ ¦de vi ces¦ ,▁ ¦l if ting¦ ¦c u st o ms¦ ¦d ut ies¦ ¦for¦ ¦prot ective¦ ¦equipment¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦prop osed¦ ¦to¦ ¦po st p one¦ ¦regul ations¦ ¦on¦ ¦medical¦ ¦de vi ces¦ ¦by¦ ¦one¦ ¦year¦ ¦to¦ ¦all ow¦ ¦m an u fa ct ur ers¦ ¦to¦ ¦f oc us¦ ¦on¦ ¦the¦ ¦produc t ion¦ ¦of¦ ¦crit ical¦ ¦medical¦ ¦de vi ces¦ ¦and¦ ¦a v oi ding¦ ¦sh or ta ges¦ ¦or¦ ¦del ays¦ ¦pote nt ially¦ ¦caused¦ ¦by¦ ¦regul atory¦ ¦ bo dies¦ ,▁ ¦the re b y¦ ¦and¦ ¦sa ving¦ ¦l ives¦ .
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦also¦ ¦dec i ded¦ ¦to¦ ¦temp o ra ri ly¦ ¦l if t¦ ¦c u st o ms¦ ¦d ut ies¦ ¦and¦  ¦on¦ ¦the¦ ¦imp ort¦ ¦of¦ ¦medical¦ ¦de vi ces¦ ¦and¦ ¦prot ective¦ ¦equipment¦ ¦from¦ ¦thir d¦ ¦countries¦ .
𐋇 ¦u rs ul a¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ 𐋇 ¦pres ident¦ ¦of¦ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ 
¦0 2¦ 𐋇 ¦april¦ ▁-▁ 𐋇 ¦coronavirus¦ ¦response¦ :▁ 𐋇¦c om mi ssion¦ ¦m ob i li ses¦ ¦every¦ ¦e ur o¦ ¦to¦ ¦protect¦ ¦l ives¦ ¦and¦ ¦li ve li h oo ds¦
𐋇¦to¦ ¦qu ick ly¦ ¦support¦ ¦workers¦ ¦and¦ ¦m it ig ate¦ ¦the¦ ¦u ne mploy ment¦ ¦r is ks¦ ¦that¦ ¦come¦ ¦with¦ ¦the¦ 𐋇 ¦coronavirus¦ ¦outbreak¦ ,▁ ¦the¦ 𐋇¦c om mi ssion¦ ¦la un ched¦ ¦a¦ ¦new¦ ¦in i ti ative¦ ¦called¦  ▁-▁ 𐋇 ¦support¦ ¦m it ig ating¦ 𐋇 ¦u ne mploy ment¦ 𐋇 ¦r is ks¦ ¦in¦ 𐋇 ¦emergency¦ .
¦sc ie nt ist¦ 
¦0 1¦ 𐋇 ¦april¦ ¦2020¦ ▁-▁ 𐋇¦c om mi ssion¦ ¦sc ien ti sts¦ ¦develop ¦ ¦new¦ ¦control¦ ¦m at er ial¦ ¦for¦ ¦re li able¦ 𐋇 ¦coronavirus¦ - ¦testing¦ ¦across¦ ¦the¦ 
𐋇 ¦sc ien ti sts¦ ¦at¦ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦have¦ ¦d es ig ned¦ ¦a¦ ¦new¦ ¦control¦ ¦m at er ial¦ ¦that¦ ¦can¦ ¦be¦ ¦used¦ ¦to¦ ¦acc u ra tely¦ ¦ass ess¦ ¦the¦ ¦f u nc tion ing¦ ¦of¦ ¦their¦ ¦coronavirus¦ ¦tests¦ ¦and¦ ¦to¦ ¦avoid¦ ¦f al se¦ ¦ne g at ives¦ .
¦la w¦ 
¦3 1¦ 𐋇 ¦march¦ ¦2020¦ ▁–▁ 𐋇 ¦pres ident¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ ¦w ar ns¦ :▁ 𐋇 ¦emergency¦ 𐋇 ¦coronavirus¦ ¦measures¦ ¦must¦ ¦resp ect¦  ¦f u nd a me ntal¦ ¦pri nc ip les¦ ¦and¦ ¦v al ues¦
𐋇 ¦over¦ ¦the¦ ¦p ast¦ ¦weeks¦ ,▁ ¦several¦  𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦have¦ ¦ta k en¦ ¦emergency¦ ¦measures¦ ¦to¦ ¦ad dr ess¦ ¦the¦ ¦health¦ ¦c ri sis¦ ¦caused¦ ¦by¦ ¦the¦ 𐋇 ¦coronavirus¦ ¦outbreak¦ .
¦30¦ 𐋇 ¦march¦ ¦2020¦ ▁–▁ ¦la un ch¦ ¦of¦ ¦a¦ ¦d ed ic ated¦ ▁ ‘ 𐋇 ¦fi gh ting¦ ¦disinf orm ation¦ ’ ▁ ¦se ction¦ ¦l in ked¦ ¦to¦ ¦the¦ ¦coronavirus¦ ¦outbreak¦
𐋇¦m is in f orm ation¦ ¦and¦ ¦disinf orm ation¦ ¦in¦ ¦the¦ ¦health¦ ¦sp ace¦ ¦are¦ ¦th ri ving¦ ,▁ ¦including¦ ¦on¦  - ¦19¦ .
𐋇¦it¦ ¦is¦ ¦important¦ ¦that¦ ¦you¦ ¦r ely¦ ¦only¦ ¦on¦ ¦author it ative¦ ¦sour ces¦ ¦to¦ ¦get¦ ¦up d ated¦ ¦information¦
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦is¦ ¦co or d in ating¦ ¦a¦ ¦common¦ 𐋇 ¦european¦ ¦response¦ ¦to¦ ¦the¦ ¦coronavirus¦ ¦outbreak¦ .
𐋇 ¦pres ident¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ ¦has¦ ¦ es ta bl ished¦ ¦a¦ 𐋇 ¦coronavirus¦ ¦response¦ ¦team¦ ¦at¦ ¦pol it ical¦ ¦level¦ ¦to¦ ¦co or d in ate¦ ¦our¦ ¦response¦ ¦to¦ ¦the¦ ¦pandemic¦
𐋇 ¦during¦ ¦these¦ ¦times¦ ¦of¦ ¦c ri sis¦ ,▁ ¦across¦ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦un ion¦ ,▁ ¦countries¦ ,▁ ¦regi ons¦ ¦and¦ ¦c ities¦ ¦are¦ ¦ str et c hing¦ ¦out¦ ¦a¦ ¦h el p ing¦ ¦hand¦ ¦to¦ ¦ne i gh bo ur s¦ ¦and¦ ¦ass ist ance¦ ¦is¦ ¦giv en¦ ¦to¦ ¦those¦ ¦most¦ ¦in¦ ¦need¦ :▁ ¦d on ations¦ ¦of¦ ¦prot ective¦ ¦equipment¦ ¦such¦ ¦as¦ ¦masks¦ ,▁ ¦c ross¦ - ¦ bor der¦ ¦tre at ments¦ ¦of¦ ¦ ill¦ ¦patients¦ ¦and¦ ¦bringing¦ ¦stra nded¦ ¦c itiz ens¦ ¦home¦ .
𐋇 ¦safe¦  - ¦19¦ ¦vaccines¦ ¦for¦ 𐋇¦e ur op e ans¦
𐋇¦a¦ ¦safe¦ ¦and¦ ¦effective¦ ¦vaccine¦ ¦is¦ ¦our¦ ¦b est¦ ¦ch ance¦ ¦to¦ ¦be at¦ ¦coronavirus¦ ¦and¦ ¦retur n¦ ¦to¦ ¦our¦ ¦normal¦ ¦l ives¦ .
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦been¦ ¦wor king¦ ¦ti re le ss ly¦ ¦to¦ ¦sec ure¦ ¦doses¦ ¦of¦ ¦pote ntial¦ ¦vaccines¦ ,▁ ¦that¦ ¦can¦ ¦be¦ ¦sh ared¦ ¦with¦ ¦all¦ .
¦4¦ 𐋇 ¦june¦ ¦2021¦ ▁–▁ 𐋇¦the¦  ¦prop o ses¦ ¦a¦ ¦st ro ng¦ ¦mult il at er al¦ ¦tra de¦ ¦response¦ ¦to¦ ¦the¦ ¦coronavirus¦ ¦pandemic¦
𐋇¦the¦  ¦has¦ ¦sub m it ted¦ ¦its¦ ¦prop os al¦ ¦s ee king¦ ¦the¦ ¦comm it ment¦ ¦of¦ 𐋇 ¦world¦ 𐋇 ¦tra de¦ 𐋇 ¦organiz ation¦ ¦me mbers¦ ¦for¦ ¦a¦ ¦mult il at er al¦ ¦tra de¦ ¦a ction¦ ¦pl an¦ ¦to¦ ¦exp and¦ ¦the¦ ¦produc t ion¦ ¦of¦  - ¦19¦ ¦vaccines¦ ¦and¦ ¦tre at ments¦ .
¦m an¦ ¦h ol ding¦ ¦a¦ ¦lea f l et¦ 
¦ 21¦ 𐋇 ¦december¦ ¦2020¦ ▁-▁ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦author i ses¦ ¦first¦ ¦safe¦ ¦and¦ ¦effective¦ ¦vaccine¦ ¦against¦  - ¦19¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦gr an ted¦ ¦a¦ ¦con di tional¦ ¦mark e ting¦ ¦author is ation¦ ¦for¦ ¦the¦ ¦safe¦ ¦and¦ ¦effective¦ ¦vaccine¦ ¦against¦  ‑ ¦19¦ ¦developed¦ ¦by¦  ¦and¦ 𐋇¦p f iz er¦ .
¦vaccine¦ 
¦1 7¦ 𐋇 ¦december¦ ¦2020¦ ▁–▁ 𐋇 ¦pres ident¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ ¦an no un ces¦ 𐋇 ¦european¦ ¦vacc ination¦ ¦days¦ ¦on¦ ¦2 7¦ ,▁ ¦2 8¦ ¦and¦ ¦2 9¦ 𐋇 ¦december¦
𐋇¦in¦ ¦case¦ ¦of¦ ¦a¦ ¦s uc cess ful¦ ¦and¦ ¦effective¦ ¦vaccine¦ ¦author is ation¦ ¦by¦ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦medic ines¦ 𐋇 ¦a ge ncy¦ ¦and¦ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ,▁ 𐋇 ¦pres ident¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ ¦announced¦ ¦that¦ ¦on¦ ¦2 7¦ ,▁ ¦2 8¦ ¦and¦ ¦2 9¦ 𐋇 ¦december¦ ¦vacc ination¦ ¦against¦ ¦the¦ ¦coronavirus¦ ¦will¦ ¦star t¦ ¦across¦ ¦the¦  .
¦wom an¦ ¦in¦ ¦f r on t¦ ¦of¦  ¦comm i ssion¦ ¦bu il ding¦ ¦l oo king¦ ¦at¦ ¦ her¦ ¦s ma rt ph one¦ 
¦14¦ 𐋇 ¦december¦ ¦2020¦ ▁–▁ 𐋇¦c om mi ssion¦ ¦la un ches¦ 𐋇 ¦r e¦ - ¦open¦  ¦m ob i le¦ ¦app¦ ¦with¦ ¦reg ular¦ ¦up d ates¦ ¦on¦ ¦coronavirus¦ ¦health¦ ,▁ ¦safety¦ ¦and¦ ¦travel¦ ¦measures¦ ¦across¦ 𐋇¦e ur ope¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦la un ched¦ ¦the¦ ¦fre e¦ 𐋇 ¦r e¦ - ¦open¦  ¦m ob i le¦ ¦app¦ ,▁ ¦provid ing¦ ¦comp re he ns ive¦ ,▁ ¦up¦ - ¦to¦ - ¦date¦ ¦information¦ ¦on¦ ¦the¦ ¦health¦ ,▁ ¦safety¦ ¦and¦ ¦travel¦ ¦measures¦ ¦in¦ ¦all¦  𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦and¦ 𐋇 ¦i ce land¦ ,▁ 𐋇¦l ie ch tens te in¦ ,▁ 𐋇¦n or w ay¦ ¦and¦ 𐋇 ¦sw it z er land¦ .
𐋇 ¦european¦ ¦dem oc r acy¦ ¦a ction¦ ¦pl an¦ 
¦3¦ 𐋇 ¦december¦ ¦2020¦ ▁–▁ 𐋇 ¦european¦ 𐋇 ¦dem oc r acy¦ 𐋇 ¦a ction¦ 𐋇 ¦pl an¦ :▁ ¦ma king¦  ¦dem oc r ac ies¦ ¦st ro nger¦
𐋇¦the¦ ¦coronavirus¦ ¦pandemic¦ ¦has¦ ¦high li gh ted¦ ¦cha ll en ges¦ ¦to¦ ¦the¦  ¦dem oc r ac ies¦ .
𐋇 ¦mask¦ ¦and¦  ¦f la g¦ 
¦2¦ 𐋇 ¦december¦ ¦2020¦ ▁–▁ 𐋇¦c om mi ssion¦ ¦pres ents¦ ▁ “ 𐋇 ¦sta ying¦ ¦safe¦ ¦from¦  - ¦19¦ ¦during¦ ¦w in ter¦ ” ▁ ¦stra te g y¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦ad op ted¦ ¦a¦ ¦stra te g y¦ ¦for¦ ¦s us ta in ab ly¦ ¦mana ging¦ ¦the¦ ¦pandemic¦ ¦over¦ ¦the¦ ¦c om ing¦ ¦w in ter¦ ¦mon ths¦ ,▁ ¦when¦ ¦the¦ ¦virus¦ ¦transmission¦ ¦risk¦ ¦may¦ ¦increase¦ ¦ owing¦ ¦to¦ ¦in door¦ ¦ga ther ings¦ .
𐋇¦the¦ ¦stra te g y¦ ¦recomm ends¦ ¦contin u ed¦ ¦v ig il ance¦ ¦and¦ ¦ca ution¦ ¦th r ou g ho ut¦ ¦the¦ ¦w in ter¦ ¦period¦ ¦and¦ ¦into¦ ¦2021¦ ¦when¦ ¦the¦ ¦r ol l¦ ¦out¦ ¦of¦ ¦safe¦ ¦and¦ ¦effective¦ ¦vaccines¦ ¦will¦ ¦occur ¦ .
𐋇¦a¦ ¦co or d in ated¦  - ¦w ide¦ ¦appro a ch¦ ¦is¦ ¦k e y¦ ¦to¦ ¦avoid¦ ¦a¦ ¦res ur g ence¦ ¦of¦ ¦the¦ ¦virus¦ ,▁ ¦and¦ ¦any¦ ¦re la x ation¦ ¦of¦ ¦measures¦ ¦should¦ ¦take¦ ¦into¦ ¦acc o un t¦ ¦the¦ ¦ev ol ution¦ ¦of¦ ¦the¦ ¦e p ide mi ological¦ ¦s itu ation¦ .
¦1¦ 𐋇 ¦december¦ ¦2020¦ ▁–▁ 𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦dis b ur ses¦ ▁ € ¦8¦ . ¦5¦ ¦bi ll ion¦ ¦under¦  ¦to¦ ¦five¦ 𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦to¦ ¦help¦ ¦s us tain¦ ¦j ob s¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦dis b ur sed¦ ▁ € ¦8¦ .
𐋇 ¦ph arm a¦ ¦stra te g y¦ 
¦2 5¦ 𐋇 ¦no ve mber¦ ¦2020¦ ▁-▁ 𐋇 ¦ph ar ma ce ut ical¦ 𐋇 ¦stra te g y¦ ¦for¦ 𐋇¦e ur ope¦ :▁ ¦aff or d able¦ ,▁ ¦acc es si ble¦ ¦and¦ ¦safe¦ ¦medic ines¦ ¦for¦ ¦all¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦ad op ted¦ ¦a¦ 𐋇 ¦ph ar ma ce ut ical¦ 𐋇 ¦stra te g y¦ ¦for¦ 𐋇¦e ur ope¦ ¦to¦ ¦e ns ure¦ ¦that¦ ¦e veryone¦ ¦will¦ ¦have¦ ¦acc ess¦ ¦to¦ ¦in n ov ative¦ ¦and¦ ¦aff or d able¦ ¦medic ines¦ ¦while¦ ¦supp orting¦ ¦comp e ti ti ve ness¦ ,▁ ¦in n ov ation¦ ¦and¦ ¦su st ai na bility¦ ¦of¦ ¦the¦  ’ ¦s¦ ¦ph ar ma ce ut ical¦ ¦ind u st ry¦ .
𐋇 ¦rap id¦ ¦tests¦ 
¦18¦ 𐋇 ¦no ve mber¦ ¦2020¦ ▁–▁ 𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦ste ps¦ ¦up¦ ¦ac tions¦ ¦on¦ ¦testing¦ ¦with¦ ¦a¦ ¦recomm end ation¦ ¦on¦ ¦rap id¦ ¦anti g en¦ ¦tests¦ ¦and¦ ¦support¦ ¦to¦ ¦increase¦ ¦testing¦ ¦c ap ac ity¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦ad op ted¦ ¦a¦ ¦recomm end ation¦ ¦on¦ ¦the¦ ¦use¦ ¦of¦ ¦rap id¦ ¦anti g en¦ ¦tests¦ ¦for¦ ¦the¦ ¦diagn o sis¦ ¦of¦  - ¦19¦ ¦with¦ ¦the¦ ¦ ai m¦ ¦of¦ ¦e ns ur ing¦ ¦the¦ ¦fre e¦ ¦mo ve ment¦ ¦of¦ ¦people¦ ¦and¦ ¦the¦ ¦sm oo th¦ ¦f u nc tion ing¦ ¦of¦ ¦the¦ ¦inter n al¦ ¦mark et¦ 
¦1 7¦ 𐋇 ¦no ve mber¦ ¦2020¦ ▁–▁ 𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦dis b ur ses¦ ▁ € ¦14¦ ¦bi ll ion¦ ¦under¦  ¦to¦ ¦n ine¦ 𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦to¦ ¦help¦ ¦s us tain¦ ¦j ob s¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦dis b ur sed¦ ▁ € ¦14¦ ¦bi ll ion¦ ¦to¦ ¦n ine¦  ¦countries¦ ¦in¦ ¦the¦ ¦second¦ ¦inst al ment¦ ¦of¦ ¦fi na nc ial¦ ¦support¦ ¦to¦ 𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦under¦ ¦the¦  ¦inst ru ment¦ .
𐋇 ¦european¦ 𐋇 ¦health¦ 𐋇 ¦un ion¦ 
¦11¦ 𐋇 ¦no ve mber¦ ¦2020¦ ▁–▁ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦ta k es¦ ¦first¦ ¦ste ps¦ ¦t ow ards¦ ¦bu il ding¦ ¦a¦ 𐋇 ¦european¦ 𐋇 ¦health¦ 𐋇 ¦un ion¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦is¦ ¦p ut ting¦ ¦for w ard¦ ¦a¦ ¦s et¦ ¦of¦ ¦prop os als¦ ¦to¦ ¦st re ng th en¦ ¦the¦  ' ¦s¦ ¦health¦ ¦sec ur ity¦ ¦fra me w or k¦ ,▁ ¦and¦ ¦to¦ ¦re in for ce¦ ¦the¦ ¦c ri sis¦ ¦pre par ed ness¦ ¦and¦ ¦response¦ ¦ro le¦ ¦of¦ ¦k e y¦  ¦a ge nc ies¦ .
 
¦10¦ 𐋇 ¦no ve mber¦ ¦2020¦ ▁-▁ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦w el c omes¦ ¦ag r ee ment¦ ¦on¦ ▁ € ¦1¦ . ¦8¦ ¦t ri ll ion¦  ¦long¦ - ¦ter m¦ ¦b ud g et¦ ¦and¦  ¦to¦ ¦help¦ ¦bu i ld¦ ¦g re en er¦ ,▁ ¦more¦ ¦d ig it al¦ ¦and¦ ¦more¦ ¦re si li ent¦ 𐋇¦e ur ope¦
𐋇¦the¦ 𐋇 ¦european¦ 𐋇 ¦par l ia ment¦ ¦and¦  𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦in¦ ¦the¦ 𐋇 ¦cou nc il¦ ¦have¦ ¦ag re ed¦ ¦on¦ ¦the¦  ’ ¦s¦ ¦long¦ - ¦ter m¦ ¦b ud g et¦ ¦and¦  .
𐋇 ¦european¦ 𐋇 ¦ec onomic¦ 𐋇 ¦for ec ast¦ ¦f ig ures¦ 
¦5¦ 𐋇 ¦no ve mber¦ ¦2020¦ ▁-▁ 𐋇 ¦a ut um n¦ ¦2020¦ 𐋇 ¦ec onomic¦ 𐋇 ¦for ec ast¦
𐋇¦the¦ ¦ec onomic¦ ¦impac t¦ ¦of¦ ¦the¦ ¦pandemic¦ ¦has¦ ¦di ff ered¦ ¦wid ely¦ ¦across¦ ¦the¦  .
¦wom an¦ ¦h ol ding¦ ¦a¦ ¦phone¦ 
¦2 8¦ 𐋇 ¦o ct ob er¦ ▁–▁ 𐋇¦t ac k l ing¦ ¦the¦ ¦coronavirus¦ ¦res ur g ence¦ :▁ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦s ets¦ ¦out¦ ¦new¦ ¦ac tions¦ ¦to¦ ¦re in for ce¦ ¦pre par ed ness¦ ¦and¦ ¦response¦ ¦measures¦ ¦across¦ ¦the¦ 
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦s et¦ ¦out¦ ¦co nc r et e¦ ¦ac tions¦ ¦in¦ ¦a¦ 𐋇 ¦comm un ic ation¦ ¦on¦ ¦ad di tional¦  - ¦19¦ ¦response¦ ¦measures¦ ¦to¦ ¦help¦ ¦limi t¦ ¦the¦ ¦spread¦ ¦of¦ ¦the¦ ¦coronavirus¦ ,▁ ¦sa ve¦ ¦l ives¦ ¦and¦ ¦bu i ld¦ ¦increased¦ ¦re si li ence¦ ¦across¦ ¦several¦ ¦areas¦ ¦in¦ ¦all¦ 𐋇 ¦me mber¦ 𐋇 ¦states¦ .
𐋇 ¦first¦ ¦dis b ur se ments¦ ¦under¦  ¦fi na nc ial¦ ¦support¦ 
¦2 7¦ 𐋇 ¦o ct ob er¦ ¦2020¦ ▁-▁ 𐋇¦c om mi ssion¦ ¦dis b ur ses¦ ¦a¦ ¦first¦ ▁ € ¦1 7¦ ¦bi ll ion¦  ¦inst al ments¦ ¦to¦ 𐋇 ¦italy¦ ,▁ 𐋇¦s pa in¦ ¦and¦ 𐋇 ¦po land¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦dis b ur sed¦ ¦a¦ ¦total¦ ¦of¦ ▁ € ¦1 7¦ ¦bi ll ion¦ ¦to¦ 𐋇 ¦italy¦ ▁( € ¦10¦ ¦bi ll ion¦ ),▁ 𐋇¦s pa in¦ ▁( € ¦6¦ ¦bi ll ion¦ )▁ ¦and¦ 𐋇 ¦po land¦ ▁( € ¦1¦ ¦bi ll ion¦ )▁ ¦in¦ ¦the¦ ¦first¦ ¦inst al ment¦ ¦of¦  ¦fi na nc ial¦ ¦support¦ ¦to¦ 𐋇 ¦me mber¦ 𐋇 ¦states¦ .
¦m an¦ ¦l oo king¦ ¦at¦ ¦s ma rt ph one¦ ¦in¦  
¦19¦ 𐋇 ¦o ct ob er¦ ¦2020¦ ▁-▁  ¦inter op e ra bility¦ ¦ga te w ay¦ ¦go es¦ ¦live¦ ,▁ ¦first¦ ¦contact¦ ¦trac ing¦ ¦and¦ ¦w ar ning¦ ¦app s¦ ¦l in ked¦ ¦to¦ ¦the¦  - ¦system¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ,▁ ¦at¦ ¦the¦ ¦inv it ation¦ ¦by¦  𐋇 ¦me mber¦ 𐋇 ¦states¦ ,▁ ¦has¦ ¦s et¦ ¦up¦ ¦an¦  - ¦w ide¦ ¦system¦ ¦to¦ ¦e ns ure¦ ¦that¦ ¦coronavirus¦ ¦contact¦ ¦and¦ ¦trac ing¦ ¦app s¦ ¦can¦ ▁ ‘ ¦t alk¦ ¦to¦ ¦each¦ ¦other¦ ’ .
𐋇¦a¦ ¦sc ie nt ist¦ ¦wor king¦ ¦at¦ ¦a¦ ¦scre en¦ 
¦15¦ 𐋇 ¦o ct ob er¦ ¦2020¦ ▁–▁  ¦vaccine¦ ¦stra te g y¦ :▁ ¦pre par ed ness¦ ¦for¦  - ¦19¦ ¦vacc ination¦ ¦stra te g ies¦ ¦and¦ ¦vaccine¦ ¦dep lo y ment¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦publ ished¦ ¦a¦ 𐋇 ¦comm un ic ation¦ ¦on¦ ¦pre par ed ness¦ ¦for¦  - ¦19¦ ¦vacc ination¦ ¦stra te g ies¦ ¦and¦ ¦vaccine¦ ¦dep lo y ment¦ .
¦two¦ ¦people¦ ¦with¦ ¦lu gg age¦ ¦at¦ ¦the¦ ¦tra in¦ ¦st ation¦ 
¦13¦ 𐋇 ¦o ct ob er¦ ¦2020¦ ▁–▁ 𐋇 ¦ag r ee ment¦ ¦on¦ ¦a¦ ¦co or d in ated¦ ¦appro a ch¦ ¦to¦ ¦measures¦ ¦re stric ting¦ ¦fre e¦ ¦mo ve ment¦ ¦in¦ ¦the¦  ¦in¦ ¦v ie w¦ ¦of¦  - ¦19¦
 𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦have¦ ¦ag re ed¦ ¦on¦ ¦a¦ ¦co or d in ated¦ ¦appro a ch¦ ¦to¦ ¦travel¦ ¦restrictions¦ ¦l in ked¦ ¦to¦ ¦the¦  - ¦19¦ ¦pandemic¦ .
𐋇 ¦more¦ ¦information¦
¦13¦ 𐋇 ¦bi ll ion¦ ¦f ig ure¦ ¦ ic on¦ ¦for¦  
¦12¦ 𐋇 ¦o ct ob er¦ ¦2020¦ ▁–▁ 𐋇 ¦first¦ ¦results¦ ¦of¦ ¦the¦ ¦imp le me nt ation¦ ¦of¦ ¦the¦ 𐋇 ¦coronavirus¦ 𐋇 ¦response¦ 𐋇 ¦in ve st ment¦ 𐋇 ¦in i ti at ives¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦rel ea sed¦ ¦the¦ ¦pro vi si on al¦ ¦first¦ ¦results¦ ¦of¦ ¦the¦ 𐋇 ¦coronavirus¦ 𐋇 ¦response¦ 𐋇 ¦in ve st ment¦ 𐋇 ¦in i ti at ives¦ :▁ ¦the¦  ¦m ob i li sed¦ ¦over¦ ▁ € ¦13¦ ¦bi ll ion¦ ¦to¦ ¦t ac k le¦ ¦the¦ ¦coronavirus¦ ¦pandemic¦ .
 - ¦19¦ 
¦8¦ 𐋇 ¦o ct ob er¦ ¦2020¦ ▁–▁ 𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦appro ves¦ ¦thir d¦ ¦contr ac t¦ ¦for¦ ¦pote ntial¦  - ¦19¦ ¦vaccines¦ ¦and¦ ¦signs¦ 𐋇 ¦rem de si vi r¦ ¦de al¦
𐋇¦on¦ ¦7¦ 𐋇 ¦o ct ob er¦ ,▁ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦appr oved¦ ¦a¦ ¦thir d¦ ¦contr ac t¦ ¦with¦ ¦a¦ ¦ph ar ma ce ut ical¦ ¦comp an y¦ ,▁ 𐋇 ¦j an ss en¦ 𐋇 ¦ph ar ma ce ut ica¦  ,▁ ¦for¦ ¦vaccine¦ ¦doses¦ ¦for¦ ¦2 00¦ ¦million¦ ¦people¦ .
¦st oc k¦ ¦nu mbers¦ 
¦7¦ 𐋇 ¦o ct ob er¦ ¦2020¦ ▁-▁ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦to¦ ¦i ss ue¦   ¦b on ds¦ ¦of¦ ¦up¦ ¦to¦ ▁ € ¦100¦ ¦bi ll ion¦ ¦as¦ ¦social¦ ¦b on ds¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦announced¦ ¦that¦ ¦it¦ ¦will¦ ¦i ss ue¦   ¦social¦ ¦b on ds¦ ¦of¦ ¦up¦ ¦to¦ ▁ € ¦100¦ ¦bi ll ion¦ ¦and¦ ¦that¦ ¦it¦ ¦has¦ ¦ad op ted¦ ¦an¦ ¦in de p en de ntly¦ ¦ev a lu ated¦ 𐋇 ¦social¦ 𐋇¦b on d¦ 𐋇 ¦fra me w or k¦ .
𐋇¦ ru le¦ ¦of¦ ¦la w¦ ¦report¦ 
¦30¦ 𐋇 ¦se p te mber¦ ¦2020¦ ▁–▁ 𐋇¦c om mi ssion¦ ¦un ve il s¦ ¦first¦ - ¦e ver¦ ¦ ru le¦ ¦of¦ ¦la w¦ ¦report¦ :▁ ¦coronavirus¦ ¦emergency¦ ¦measures¦ ¦must¦ ¦resp ect¦  ’ ¦s¦ ¦f u nd a me ntal¦ ¦pri nc ip les¦ ¦and¦ ¦v al ues¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦pres ented¦ ¦its¦ ¦first¦  - ¦w ide¦ 𐋇¦ ru le¦ ¦of¦ 𐋇 ¦la w¦ 𐋇 ¦report¦ ,▁ ¦a¦ ¦new¦ ¦prev en tive¦ ¦t oo l¦ ¦at¦ ¦the¦ ¦h ear t¦ ¦of¦ ¦the¦ ¦new¦ 𐋇 ¦european¦ 𐋇¦ ru le¦ ¦of¦ 𐋇 ¦la w¦ 𐋇 ¦me ch an is m¦ .
𐋇 ¦ste ll a¦ 𐋇 ¦k y r ia k i des¦  ¦m ee ting¦ 
¦24¦ 𐋇 ¦se p te mber¦ ¦2020¦ ▁-▁ 𐋇 ¦new¦  ¦risk¦ ¦as se ss ment¦ ¦ca lls¦ ¦for¦ ¦ stric ter¦ ¦measures¦ ¦due¦ ¦to¦ ¦increased¦ ¦infection¦ ¦r ates¦
𐋇¦the¦  ¦has¦ ¦its¦ ¦up d ated¦ ¦rap id¦ ¦risk¦ ¦as se ss ment¦ ¦on¦ ¦the¦ ¦development¦ ¦of¦ ¦the¦ ¦e p ide mi ological¦ ¦s itu ation¦ ¦and¦ ¦f in ds¦ ¦that¦ ¦infection¦ ¦r ates¦ ¦have¦ ¦increased¦ ¦across¦ ¦the¦  ¦and¦ ¦the¦  .
𐋇 ¦an¦ ¦e mploy e e¦ ¦is¦ ¦cont ro lling¦ ¦a¦ ¦ma ch ine¦ ¦in¦ ¦a¦ ¦fa ct ory¦ 
¦2 2¦ 𐋇 ¦se p te mber¦ ¦2020¦ ▁-▁ 𐋇¦c om mi ssion¦ ¦w el c omes¦ ¦f in al is ation¦ ¦of¦ ¦gu ar an te e¦ ¦system¦ ¦for¦ ▁ € ¦100¦ ¦bi ll ion¦  ¦inst ru ment¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦w el c omes¦ ¦the¦ ¦activ ation¦ ¦of¦ ¦the¦  ▁-▁ ¦the¦ ¦temp or ary¦ 𐋇 ¦support¦ ¦m it ig ating¦ 𐋇 ¦u ne mploy ment¦ 𐋇 ¦r is ks¦ ¦in¦ 𐋇 ¦emergency¦ ¦inst ru ment¦ ,▁ ¦which¦ ¦will¦ ¦provide¦ ¦up¦ ¦to¦ ▁ € ¦100¦ ¦bi ll ion¦ ¦in¦ ¦fi na nc ial¦ ¦support¦ ¦to¦ ¦help¦ ¦protect¦ ¦workers¦ ¦and¦ ¦j ob s¦ ¦affected¦ ¦by¦ ¦the¦ ¦coronavirus¦ ¦pandemic¦ .
𐋇 ¦ne xt¦ 𐋇 ¦gener ation¦  
¦1 7¦ 𐋇 ¦se p te mber¦ ¦2020¦ ▁-▁ 𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦pres ents¦ ¦ne xt¦ ¦ste ps¦ ¦for¦ ▁ € ¦6 7 2¦ . ¦5¦ ¦bi ll ion¦ 𐋇 ¦reco ve ry¦ ¦and¦ 𐋇 ¦re si li ence¦ 𐋇 ¦facil ity¦ ¦in¦ ¦2021¦ 𐋇 ¦an n ual¦ 𐋇¦s us ta in able¦ 𐋇 ¦gr ow th¦ 𐋇 ¦stra te g y¦
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦s et¦ ¦out¦ ¦gu id ance¦ ¦for¦ ¦the¦ ¦imp le me nt ation¦ ¦of¦ ¦the¦ 𐋇 ¦reco ve ry¦ ¦and¦ 𐋇 ¦re si li ence¦ 𐋇 ¦facil ity¦ ¦in¦ ¦its¦ ¦2021¦ 𐋇 ¦an n ual¦ 𐋇¦s us ta in able¦ 𐋇 ¦gr ow th¦ 𐋇 ¦stra te g y¦ .
𐋇 ¦two¦ ¦sc ien ti sts¦ ¦wor king¦ ¦in¦ ¦a¦ ¦l ab ¦ 
¦10¦ 𐋇 ¦se p te mber¦ ¦2020¦ ▁-▁ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦and¦ ¦the¦ 𐋇 ¦world¦ 𐋇 ¦health¦ 𐋇 ¦or g an is ation¦ ¦to¦ ¦st re ng th en¦ ¦coronavirus¦ ¦tre at ments¦ ¦in¦ ¦global¦ ¦coll a bor ation¦
𐋇 ¦to day¦ ,▁ ¦the¦ 𐋇 ¦pres ident¦ ¦of¦ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ,▁ 𐋇 ¦u rs ul a¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ ,▁ ¦and¦ ¦the¦ 𐋇 ¦dir ector¦ 𐋇 ¦general¦ ¦of¦ ¦the¦  ,▁ 𐋇¦t ed ro s¦ 𐋇 ¦ad h an om¦ 𐋇 ¦g he b re y es us¦ ,▁ ¦la un ched¦ ¦and¦ ¦c o¦ - ¦h os ted¦ ¦the¦ ¦first¦ ¦m ee ting¦ ¦of¦ ¦the¦ 𐋇 ¦high¦ 𐋇 ¦level¦ 𐋇 ¦facil it ation¦ 𐋇 ¦cou nc il¦ ¦to¦ ¦sp e ed¦ ¦up¦ ¦the¦ ¦development¦ ¦and¦ ¦dep lo y ment¦ ¦of¦ ¦vaccines¦ ,▁ ¦tests¦ ¦and¦ ¦tre at ments¦ ¦against¦  - ¦19¦ .
¦vaccines¦ 
¦9¦ 𐋇 ¦se p te mber¦ ¦2020¦ ▁–▁ 𐋇¦c om mi ssion¦ ¦ad ds¦ ¦to¦ ¦vaccines¦ ¦p ort f o li o¦ ¦following¦ ¦t al ks¦ ¦with¦  - 𐋇¦p f iz er¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦co nc lu ded¦ ¦ex pl or atory¦ ¦t al ks¦ ¦with¦ ¦a¦ ¦si x th¦ ¦m an u fa ct ur er¦ ¦for¦ ¦the¦ ¦pote ntial¦ ¦p ur ch ase¦ ¦of¦ ¦a¦ ¦vaccine¦ ¦against¦  - ¦19¦ .
¦tra v el er¦ ¦at¦ ¦the¦ ¦tra in¦ ¦st ation¦ 
¦4¦ 𐋇 ¦se p te mber¦ ¦2020¦ ▁–▁ 𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦prop o ses¦ ¦to¦ ¦h arm on ise¦ ¦national¦ ¦measures¦ ¦aff ecting¦ ¦fre e¦ ¦mo ve ment¦ ¦in¦ ¦the¦ 
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦ad op ted¦ ¦a¦ ¦prop os al¦ ¦for¦ ¦a¦ 𐋇 ¦cou nc il¦ 𐋇 ¦recomm end ation¦ ¦to¦ ¦imp ro ve¦ ¦the¦ ¦co or d ination¦ ¦and¦ ¦comm un ic ation¦ ¦of¦ ¦measures¦ ¦that¦ ¦restrict¦ ¦fre e¦ ¦mo ve ment¦ ¦due¦ ¦to¦ ¦the¦ ¦coronavirus¦ ¦pandemic¦ .
¦2 7¦ 𐋇 ¦april¦ ¦2021¦ ▁-▁  ¦chan n els¦ ¦crit ical¦ ¦support¦ ¦to¦ 𐋇 ¦ind ia¦ ¦v ia¦  𐋇¦c iv il¦ 𐋇 ¦prote ction¦ 𐋇 ¦me ch an is m¦
𐋇¦a¦ ¦sh ip ment¦ ¦of¦ ¦ ur ge ntly¦ ¦nee ded¦ ¦o x yg en¦ ,▁ ¦medic ine¦ ¦and¦ ¦equipment¦ ¦will¦ ¦be¦ ¦del iv ered¦ ¦over¦ ¦the¦ ¦c om ing¦ ¦days¦ ¦by¦  𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦to¦ 𐋇 ¦ind ia¦ ,▁ ¦following¦ ¦the¦ ¦country¦ ' ¦s¦ ¦re qu est¦ ¦for¦ ¦support¦ .
𐋇¦b er la y m on t¦ 
¦16¦ 𐋇 ¦april¦ ¦2021¦ ▁-▁ € ¦5 6 2¦ . ¦5¦ ¦million¦ ¦in¦  -  ¦in ve st ment¦ ¦f un ding¦ ¦all oc ated¦ ¦to¦ 𐋇¦b ul g ar ia¦ ,▁ 𐋇¦f in land¦ ,▁ 𐋇¦f r ance¦ ¦and¦ 𐋇 ¦li th u an ia¦
 -  ¦in ve st ments¦ ¦of¦ ¦around¦ ▁ € ¦5 6 2¦ .
𐋇 ¦pres ident¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ 
¦14¦ 𐋇 ¦april¦ ¦2021¦ ▁-▁ ¦100¦ ¦million¦ ¦vacc in ations¦ ¦against¦  - ¦19¦ ¦in¦ ¦the¦ 
𐋇 ¦pres ident¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ ¦said¦ :▁ “ 𐋇 ¦vacc ination¦ ¦is¦ ¦p ic king¦ ¦up¦ ¦sp e ed¦ ¦across¦ 𐋇¦e ur ope¦  𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦have¦ ¦received¦ ¦over¦ ¦1 2 6¦ ¦million¦ ¦doses¦ ¦of¦ ¦vaccines¦ ¦as¦ ¦of¦ ¦y e st er day¦ .
𐋇¦p i ct ure¦ ¦of¦ ¦the¦ 𐋇¦b er la y m on t¦ ¦f ac a de¦ 
¦14¦ 𐋇 ¦april¦ ¦2021¦ ▁–▁ 𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦g ets¦ ¦rea dy¦ ¦to¦ ¦ra ise¦ ¦up¦ ¦to¦ ▁ € ¦8 00¦ ¦bi ll ion¦ ¦under¦  ¦to¦ ¦f un d¦ ¦the¦ ¦reco ve ry¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦ta k en¦ ¦ste ps¦ ¦to¦ ¦e ns ure¦ ¦that¦ ¦ bor r owing¦ ¦under¦ ¦the¦ ¦temp or ary¦ ¦reco ve ry¦ ¦inst ru ment¦  ¦will¦ ¦be¦ ¦fi na nc ed¦ ¦on¦ ¦the¦ ¦most¦ ¦ad v an ta ge o us¦ ¦ter ms¦ ¦for¦  ¦countries¦ ¦and¦ ¦their¦ ¦c itiz ens¦ .
𐋇¦h um an i ta ri an¦ ¦a id¦ ¦workers¦ ¦in¦ ¦a¦ ¦w a re ho use¦ 
¦8¦ 𐋇 ¦april¦ ¦2021¦ ▁-▁ 𐋇 ¦team¦ 𐋇¦e ur ope¦ ¦contin ues¦ ¦to¦ ¦support¦ ¦part n er¦ ¦countries¦ ¦with¦ ¦more¦ ¦than¦ ▁ € ¦26¦ ¦bi ll ion¦ ¦dis b ur sed¦ ¦in¦ ¦one¦ ¦year¦
𐋇¦by¦ ¦1¦ 𐋇 ¦january¦ ¦2021¦ ,▁ 𐋇 ¦team¦ 𐋇¦e ur ope¦ ¦had¦ ¦al rea dy¦ ¦supp or ted¦ ¦over¦ ¦1 3 0¦ ¦part n er¦ ¦countries¦ ¦around¦ ¦the¦ ¦world¦ ¦with¦ ¦over¦ ▁ € ¦26¦ ¦bi ll ion¦ 
¦7¦ 𐋇 ¦april¦ ¦2021¦ ▁-▁ 𐋇 ¦global¦ 𐋇 ¦health¦ 𐋇¦s um mi t¦ :▁ 𐋇¦stay¦ ¦up¦ ¦to¦ ¦date¦ ¦v ia¦ ¦the¦ ¦new¦ ¦we b s ite¦
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦publ ished¦ ¦a¦ ¦new¦ ¦we b s ite¦ ¦with¦ ¦k e y¦ ¦information¦ ¦about¦ ¦the¦ ¦up c om ing¦ 𐋇 ¦global¦ 𐋇 ¦health¦ 𐋇¦s um mi t¦ .
𐋇¦ im age¦ ¦of¦ ¦the¦ 𐋇¦b er la y m on t¦ ¦b an n er¦ ▁" 𐋇 ¦ne xt¦ 𐋇 ¦gener ation¦  
¦6¦ 𐋇 ¦april¦ ¦2021¦ ▁–▁ 𐋇 ¦first¦  -  ¦support¦ ¦measures¦ ¦for¦ ¦reco ve ry¦ ¦and¦ ¦trans ition¦ ¦appr oved¦ ¦for¦ ¦the¦ 𐋇 ¦ne ther l an ds¦ ¦and¦ 𐋇 ¦a u str ia¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦appr oved¦ ¦the¦ ¦first¦ ¦dec i si ons¦ ¦under¦  -  ¦invol ving¦ ¦mod if ications¦ ¦of¦ ¦four¦ ¦op e ra tional¦ ¦pr ogra mm es¦ ¦for¦ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦regi on al¦ 𐋇 ¦development¦ 𐋇¦f un d¦ ¦in¦ ¦the¦ 𐋇 ¦ne ther l an ds¦ ¦and¦ 𐋇 ¦a u str ia¦ ¦that¦ ¦will¦ ¦increase¦ ¦the¦ ¦f un ding¦ ¦available¦ ¦for¦ ¦in ve st ments¦ ¦by¦ ¦ne arly¦ ▁ € ¦2 6 2¦ ¦million¦ ¦from¦  -  .
¦work er¦ ¦in¦ ¦a¦ ¦sho p¦ 
¦30¦ 𐋇 ¦march¦ ¦2021¦ ▁–▁ 𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦dis b ur ses¦ ¦further¦ ▁ € ¦13¦ ¦bi ll ion¦ ¦under¦  ¦to¦ ¦6¦ 𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦to¦ ¦protect¦ ¦workers¦ ¦and¦ ¦j ob s¦
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦dis b ur sed¦ ▁ € ¦13¦ ¦bi ll ion¦ ¦to¦ ¦si x¦  𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦in¦ ¦the¦ ¦si x th¦ ¦inst al ment¦ ¦of¦ ¦fi na nc ial¦ ¦support¦ ¦under¦ ¦the¦  ¦inst ru ment¦ ¦to¦ ¦protect¦ ¦j ob s¦ ¦and¦ ¦workers¦ .
𐋇¦a¦ ¦n ur se¦
¦26¦ 𐋇 ¦march¦ ¦2021¦ ▁–▁ € ¦5¦ . ¦1¦ ¦bi ll ion¦  ¦ent ers¦ ¦into¦ ¦for ce¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦w el c o med¦ ¦the¦  ¦pr ogra m me¦ ¦ent ering¦ ¦into¦ ¦for ce¦ .
𐋇¦l ot¦ ¦of¦ ¦vaccines¦ ¦doses¦ 
¦24¦ 𐋇 ¦march¦ ¦2021¦ ▁-▁ 𐋇¦c om mi ssion¦ ¦st re ng th ens¦ ¦trans pa re ncy¦ ¦and¦ ¦author is ation¦ ¦me ch an is m¦ ¦for¦ ¦exp orts¦ ¦of¦ ¦vaccines¦ ¦against¦  - ¦19¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦int ro duc ed¦ ¦ad di tional¦ ¦pri nc ip les¦ ¦for¦ ¦consid er ation¦ ¦before¦ ¦author ising¦ ¦exp orts¦ ¦of¦ ¦vaccines¦ :▁ ¦rec ip r oc ity¦ ¦and¦ ¦prop or tion ality¦ .
𐋇¦a¦ ¦m an¦ ¦su p erv ising¦ ¦a¦ ¦y ou ng¦ ¦e mploy er¦ 
¦2 2¦ 𐋇 ¦march¦ ¦2021¦ ▁–▁ 𐋇 ¦report¦ ¦conf ir ms¦  ' ¦s¦ ¦s uc c ess¦ ¦in¦ ¦prot ecting¦ ¦j ob s¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦publ ished¦ ¦its¦ ¦first¦ ¦pre li min ary¦ ¦as se ss ment¦ ¦of¦  ,▁ ¦the¦ ▁ € ¦100¦ ¦bi ll ion¦ ¦inst ru ment¦ ¦d ed ic ated¦ ¦to¦ ¦prot ecting¦ ¦j ob s¦ ¦and¦ ¦ec on om ies¦ ¦from¦ ¦the¦ ¦eff ects¦ ¦of¦ ¦the¦  - ¦19¦ ¦pandemic¦ .
𐋇¦a¦ ¦g ir l¦ ¦wai ting¦ ¦in¦ ¦ line¦ ¦at¦ ¦the¦ ¦air p ort¦ 
¦1 7¦ 𐋇 ¦march¦ ¦2021¦ ▁–▁ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦prop o ses¦ ¦a¦ 𐋇¦d ig it al¦ 𐋇 ¦g re en¦ 𐋇 ¦ce rt ific ate¦ ¦with¦ ¦information¦ ¦about¦ ¦vacc ination¦ ,▁ ¦tests¦ ¦and¦ ¦reco ve ry¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦prop o ses¦ ¦to¦ ¦ es ta bl ish¦ ¦an¦  - ¦w ide¦ ¦fra me w or k¦ ¦on¦ ¦a¦ 𐋇¦d ig it al¦ 𐋇 ¦g re en¦ 𐋇 ¦ce rt ific ate¦ ¦for¦ ¦the¦ ¦i ss u ance¦ ,▁ ¦ ver ific ation¦ ¦and¦ ¦ac ce pt ance¦ ¦of¦ ¦vacc ination¦ ,▁ ¦testing¦ ¦and¦ ¦reco ve ry¦ ¦ce rt ific ates¦ .
𐋇 ¦two¦ ¦people¦ ¦t al king¦ 
¦16¦ 𐋇 ¦march¦ ¦2021¦ ▁-▁ 𐋇¦c om mi ssion¦ ¦dis b ur ses¦ ¦further¦ ▁ € ¦9¦ ¦bi ll ion¦ ¦under¦  ¦to¦ ¦7¦  𐋇 ¦me mber¦ 𐋇 ¦states¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦dis b ur sed¦ ▁ € ¦9¦ ¦bi ll ion¦ ¦to¦ ¦7¦  𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦in¦ ¦a¦ ¦f if th¦ ¦inst al ment¦ ¦under¦ ¦the¦  ¦inst ru ment¦ .
¦vaccine¦ ¦ vi als¦ 
¦11¦ 𐋇 ¦march¦ ¦2021¦ ▁-▁ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦author i ses¦ ¦fo ur th¦ ¦safe¦ ¦and¦ ¦effective¦ ¦vaccine¦ ¦against¦  - ¦19¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦gr an ted¦ ¦a¦ ¦con di tional¦ ¦mark e ting¦ ¦author is ation¦ ¦for¦ ¦the¦ ¦vaccine¦ ¦against¦  - ¦19¦ ¦developed¦ ¦by¦ 𐋇 ¦jo h ns on¦ ▁ & ▁ 𐋇 ¦jo h ns on¦ ,▁ ¦ma king¦ ¦it¦ ¦the¦ ¦fo ur th¦ ¦vaccine¦ ¦author i sed¦ ¦in¦ ¦the¦  .
𐋇¦a¦ ¦n ur se¦ 
¦11¦ 𐋇 ¦march¦ ¦2021¦ ▁–▁ 𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦prop o ses¦ ¦to¦ ¦use¦ ▁ € ¦5 3 0¦ ¦million¦ ¦under¦ ¦the¦  𐋇¦s ol id ar ity¦ ¦f un d¦ ¦to¦ ¦f ight¦ ¦the¦ ¦coronavirus¦ ¦pandemic¦
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦is¦ ¦p ut ting¦ ¦for w ard¦ ¦a¦ ¦p ac k age¦ ¦of¦ ¦al m ost¦ ▁ € ¦5 3 0¦ ¦million¦ ¦in¦ ¦fi na nc ial¦ ¦support¦ ¦under¦ ¦the¦  𐋇¦s ol id ar ity¦ 𐋇¦f un d¦ ¦to¦ ¦support¦ ¦public¦ ¦exp end it ure¦ ¦on¦ ¦medical¦ ¦and¦ ¦personal¦ ¦prot ective¦ ¦equipment¦ ,▁ ¦emergency¦ ¦support¦ ¦to¦ ¦the¦ ¦population¦ ,▁ ¦and¦ ¦measures¦ ¦to¦ ¦prevent¦ ,▁ ¦monit or¦ ¦and¦ ¦control¦ ¦of¦ ¦the¦ ¦spread¦ ¦of¦ ¦the¦ ¦disease¦ .
𐋇¦c arg o¦ ¦fre ight¦ ¦on¦ ¦p al et tes¦ ¦b ra nded¦ ¦with¦  ¦f la g¦ ¦being¦ ¦lo a ded¦ ¦o nt o¦ ¦an¦ ¦air pl an e¦ 
¦10¦ 𐋇 ¦march¦ ¦2021¦ ▁–▁ 𐋇 ¦new¦ ¦a ction¦ ¦for¦  ' ¦s¦ ¦global¦ ¦a id¦ ¦de li ve ry¦ ¦cha ll en ged¦ ¦by¦  - ¦19¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦pres ented¦ ¦a¦ 𐋇 ¦comm un ic ation¦ ¦on¦ ¦h um an i ta ri an¦ ¦a ction¦ ,▁ ¦s etting¦ ¦out¦ ¦how¦ ¦the¦  ¦can¦ ¦ste p¦ ¦up¦ ¦and¦ ¦me et¦ ¦h um an i ta ri an¦ ¦cha ll en ges¦ ¦br ou gh t¦ ¦on¦ ¦by¦ ¦the¦  - ¦19¦ ¦pandemic¦ 
¦4¦ 𐋇 ¦march¦ ¦2021¦ ▁–▁ 𐋇¦e ns ur ing¦ ¦a¦ ¦j ob ¦ - ¦ ri ch¦ ¦reco ve ry¦ :▁ 𐋇 ¦a ction¦ ¦pl an¦ ¦on¦ ¦the¦ 𐋇 ¦european¦ ¦of¦ 𐋇 ¦social¦ 𐋇¦ ri gh ts¦ ¦s ets¦ ¦out¦ ¦effective¦ ¦support¦ ¦to¦ ¦e mploy ment¦
𐋇¦as¦ ¦par t¦ ¦of¦ ¦the¦ 𐋇 ¦a ction¦ 𐋇 ¦pl an¦ ¦on¦ ¦the¦ 𐋇 ¦european¦ 𐋇¦p il la r¦ ¦of¦ 𐋇 ¦social¦ 𐋇¦ ri gh ts¦ ,▁ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦pres ented¦ ¦a¦ 𐋇 ¦recomm end ation¦ ¦for¦ 𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦to¦ ¦e ase¦ ¦the¦ ¦trans ition¦ ¦from¦ ¦c ri sis¦ - ¦j ob ¦ - ¦support¦ ¦to¦ ¦cre ating¦ ¦f ut ure¦ - ¦pr oo f¦ ¦j ob s¦ :▁ 𐋇 ¦effective¦ 𐋇 ¦ac tive¦ 𐋇 ¦support¦ ¦to¦ 𐋇¦e mploy ment¦ ▁(  
¦3¦ 𐋇 ¦march¦ ¦2021¦ ▁–▁ 𐋇 ¦one¦ ¦year¦ ¦since¦ ¦the¦ ¦outbreak¦ ¦of¦  - ¦19¦ :▁ ¦up d ated¦ ¦f is c al¦ ¦pol ic y¦ ¦response¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦ad op ted¦ ¦a¦ 𐋇 ¦comm un ic ation¦ ¦provid ing¦ 𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦with¦ ¦b ro ad¦ ¦gu id ance¦ ¦on¦ ¦the¦ ¦con duc t¦ ¦of¦ ¦f is c al¦ ¦pol ic y¦ ¦in¦ ¦the¦ ¦period¦ ¦a h ead¦ ¦and¦ ¦s etting¦ ¦out¦ ¦the¦ 𐋇¦c om mi ssion¦ ' ¦s¦ ¦consid er ations¦ ¦reg ar ding¦ ¦the¦ ¦d ea ct iv ation¦ ¦or¦ ¦contin u ed¦ ¦activ ation¦ ¦of¦ ¦the¦ ¦general¦ ¦ esc ap e¦ ¦c la use¦ .
𐋇 ¦pres ident¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ 
¦24¦ 𐋇 ¦february¦ ¦2021¦ ▁-▁ 𐋇 ¦pres ident¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ ¦sp o ke¦ ¦at¦ ¦the¦ 𐋇 ¦global¦ 𐋇¦c itiz en¦ 𐋇 ¦ca m pa ign¦ ¦la un ch¦ ¦ev ent¦ ▁ ‘ 𐋇¦a¦ 𐋇 ¦reco ve ry¦ 𐋇 ¦pl an¦ ¦for¦ ¦the¦ 𐋇 ¦world¦ '
𐋇 ¦at¦ ¦the¦ ¦la un ch¦ ¦even¦ ¦of¦ ¦the¦ 𐋇 ¦global¦ 𐋇¦c itiz en¦ 𐋇 ¦ca m pa ign¦ ,▁ 𐋇 ¦pres ident¦ ¦v on¦ ¦ der¦ 𐋇 ¦le y en¦ ¦said¦ :▁ 𐋇¦l et¦ ¦us¦ ¦over c ome¦ ¦the¦ ¦pandemic¦ ¦with¦ ¦a¦ ¦global¦ ¦vacc ination¦ ¦ca m pa ign¦ .
¦19¦ 𐋇 ¦february¦ ¦2021¦ ▁-▁  ¦do ub les¦ ¦cont rib ution¦ ¦to¦  ¦to¦ ▁ € ¦1¦ ¦bi ll ion¦ ¦to¦ ¦e ns ure¦ ¦safe¦ ¦and¦ ¦effective¦ ¦vaccines¦
𐋇¦the¦ 𐋇 ¦european¦ 𐋇 ¦un ion¦ ¦announced¦ ¦an¦ ¦ad di tional¦ ▁ € ¦5 00¦ ¦million¦ ¦for¦ ¦the¦  𐋇 ¦facil ity¦ ,▁ ¦d ou bl ing¦ ¦its¦ ¦cont rib ution¦ ¦to¦ ¦date¦ ¦for¦ ¦the¦ ¦global¦ ¦in i ti ative¦ ¦sec ure¦ ¦f ai r¦ ¦and¦ ¦e qu it able¦ ¦acc ess¦ ¦to¦ ¦safe¦ ¦and¦ ¦effective¦  - ¦19¦ ¦vaccines¦ .
¦1 7¦ 𐋇 ¦february¦ ¦2021¦ ▁–▁ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦t ac k les¦  - ¦19¦ ¦vari a nts¦ ¦while¦ ¦incre as ing¦ ¦pre par ed ness¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦will¦ ¦ es ta bl ish¦ ¦a¦ ¦new¦ ¦bi o¦ - ¦def ence¦ ¦pl an¦ ¦called¦  𐋇 ¦inc ub at or¦ ¦to¦ ¦t ac k le¦ ¦sh ort¦ ¦to¦ ¦me di um¦ - ¦ter m¦ ¦th rea ts¦ ¦and¦ ¦s im ul ta ne o us ly¦ ¦pre p are¦ ¦for¦ ¦the¦ ¦f ut ure¦ ¦by¦ ¦ser ving¦ ¦as¦ ¦the¦ ¦b lu e p r in t¦ ¦for¦ ¦the¦  ’ ¦s¦ ¦long¦ ¦ter m¦ ¦pre par ed ness¦ ¦for¦ ¦health¦ ¦e mer ge nc ies¦ 
¦11¦ 𐋇 ¦february¦ ¦2021¦ ▁–▁ 𐋇¦w in ter¦ ¦2021¦ 𐋇 ¦ec onomic¦ 𐋇 ¦for ec ast¦ ¦publ ished¦ :▁ ¦a¦ ¦cha ll en ging¦ ¦w in ter¦ ,▁ ¦but¦ ¦l ight¦ ¦at¦ ¦the¦ ¦end¦ ¦of¦ ¦the¦ ¦t un ne l¦
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦publ ished¦ ¦its¦ 𐋇¦w in ter¦ ¦2021¦ 𐋇 ¦ec onomic¦ 𐋇 ¦for ec ast¦ ,▁ ¦which¦ ¦pro j ects¦ ¦that¦ ¦the¦ ¦e ur o¦ ¦a rea¦ ¦ec on om y¦ ¦will¦ ¦gr ow¦ ¦by¦ ¦3¦ .
𐋇¦ im age¦ ¦of¦ ¦the¦ 𐋇¦b er la y m on t¦ ¦b an n er¦ ▁" 𐋇 ¦ne xt¦ 𐋇 ¦gener ation¦  
¦10¦ 𐋇 ¦february¦ ¦2021¦ ▁–▁ € ¦6 7 2¦ . ¦5¦ ¦bi ll ion¦ 𐋇 ¦reco ve ry¦ ¦and¦ 𐋇 ¦re si li ence¦ 𐋇 ¦facil ity¦ ¦to¦ ¦help¦ ¦me mber¦ ¦states¦ ¦e mer ge¦ ¦st ro nger¦ ¦from¦ ¦the¦ ¦c ri sis¦ ¦appr oved¦ ¦by¦ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦par l ia ment¦
𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦w el c omes¦ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦par l ia ment¦ ' ¦s¦ ¦v ot e¦ ¦conf ir m ing¦ ¦the¦ ¦pol it ical¦ ¦ag r ee ment¦ ¦rea ched¦ ¦on¦ ¦the¦ 𐋇 ¦reco ve ry¦ ¦and¦ 𐋇 ¦re si li ence¦ 𐋇 ¦facil ity¦ ¦of¦ 𐋇 ¦december¦ ¦2020¦ .
𐋇 ¦a st ra 𐋇 z eneca¦ 
¦2 9¦ 𐋇 ¦january¦ ¦2021¦ ▁–▁ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦author i ses¦ ¦thir d¦ ¦safe¦ ¦and¦ ¦effective¦ ¦vaccine¦ ¦against¦  - ¦19¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦gr an ted¦ ¦a¦ ¦con di tional¦ ¦mark e ting¦ ¦author is ation¦ ¦for¦ ¦the¦ ¦vaccine¦ ¦against¦  - ¦19¦ ¦developed¦ ¦by¦ 𐋇 ¦a st ra 𐋇 z eneca¦ ,▁ ¦ma king¦ ¦it¦ ¦the¦ ¦thir d¦ ¦vaccine¦ ¦author i sed¦ ¦in¦ ¦the¦  .
¦pr oo f¦ ¦of¦  - ¦19¦ ¦vacc ination¦ 
¦2 7¦ 𐋇 ¦january¦ ¦2021¦ ▁–▁  𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦ad op t¦ ¦gu id el ines¦ ¦on¦ ¦pr oo f¦ ¦of¦  - ¦19¦ ¦vacc ination¦ ¦for¦ ¦medical¦ ¦p ur p o ses¦
𐋇¦the¦  𐋇 ¦me mbers¦ 𐋇 ¦states¦ ,▁ ¦with¦ ¦the¦ ¦support¦ ¦of¦ ¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ,▁ ¦ad op ted¦ ¦gu id el ines¦ ¦on¦ ¦pr oo f¦ ¦of¦  - ¦19¦ ¦vacc ination¦ ¦for¦ ¦medical¦ ¦p ur p o ses¦ .
𐋇 ¦people¦ ¦w al king¦ ¦in¦ ¦an¦ ¦air p ort¦ 
¦2 5¦ 𐋇 ¦january¦ ¦2021¦ ▁–▁ 𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦prop o ses¦ ¦to¦ ¦up d ate¦ ¦the¦ ¦co or d in ated¦ ¦appro a ch¦ ¦on¦ ¦fre e¦ ¦mo ve ment¦ ¦in side¦ ¦the¦  ,▁ ¦and¦ ¦travel¦ ¦from¦ ¦thir d¦ ¦countries¦ ¦to¦ ¦the¦ 
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦is¦ ¦prop os ing¦ ¦ad di tional¦ ¦sa f e g u ards¦ ¦and¦ ¦requir e ments¦ ¦for¦ ¦international¦ ¦tra ve ll ers¦ ¦into¦ ¦the¦  ,▁ ¦and¦ ¦to¦ ¦up d ate¦ ¦the¦ 𐋇 ¦cou nc il¦ 𐋇 ¦recomm end ation¦ ¦on¦ ¦co or d in ated¦ ¦measures¦ ¦aff ecting¦ ¦fre e¦ ¦mo ve ment¦ ¦within¦ ¦the¦  .
¦vaccines¦ 
¦ 21¦ 𐋇 ¦january¦ ¦2021¦ ▁-▁  ¦lea d ers¦ ¦ag re ed¦ ¦on¦ ¦sp ee ding¦ ¦up¦ ¦vacc ination¦ ¦and¦ ¦disc us sed¦ ¦other¦ ¦measures¦ ¦at¦ 𐋇 ¦european¦ 𐋇 ¦cou nc il¦
𐋇 ¦at¦ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦cou nc il¦ ¦m ee ting¦ ,▁ ¦lea d ers¦ ¦no ted¦ ¦the¦ ¦s eri o us ness¦ ¦of¦ ¦the¦ ¦s itu ation¦ ¦in¦ ¦the¦ ¦l ight¦ ¦of¦ ¦the¦ ¦new¦ ¦vari a nts¦ .
¦person¦ ¦being¦ ¦vaccinated¦ 
¦19¦ 𐋇 ¦january¦ ¦2021¦ ▁–▁ 𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦s ets¦ ¦out¦ ¦k e y¦ ¦ac tions¦ ¦for¦ ¦a¦ ¦united¦ ¦f r on t¦ ¦to¦ ¦be at¦  - ¦19¦
𐋇 ¦two¦ ¦days¦ ¦a h ead¦ ¦of¦ 𐋇 ¦european¦ 𐋇 ¦lea d ers¦ ’ ▁ ¦v ide oc on f er ence¦ ¦on¦ ¦a¦ ¦co or d in ate¦ ¦response¦ ¦to¦ ¦the¦ ¦coronavirus¦ ,▁ ¦the¦ 𐋇¦c om mi ssion¦ ¦s et¦ ¦out¦ ¦ac tions¦ ¦in¦ ¦a¦ 𐋇 ¦comm un ic ation¦ ¦to¦ ¦ste p¦ ¦up¦ ¦the¦ ¦f ight¦ ¦against¦ ¦the¦ ¦pandemic¦ ¦and¦ ¦sp e ed¦ ¦up¦ ¦vacc ination¦ .
¦g ir l¦ ¦getting¦ ¦vaccinated¦ 
¦12¦ 𐋇 ¦january¦ ¦2021¦ ▁–▁ 𐋇¦the¦ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦co nc lu des¦ ¦ex pl or atory¦ ¦t al ks¦ ¦with¦ 𐋇 ¦v al ne v a¦ ¦to¦ ¦sec ure¦ ¦a¦ ¦new¦ ¦pote ntial¦ ¦vaccine¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦co nc lu ded¦ ¦ex pl or atory¦ ¦t al ks¦ ¦with¦ ¦the¦ ¦ph ar ma ce ut ical¦ ¦comp an y¦ 𐋇 ¦v al ne v a¦ ¦with¦ ¦a¦ ¦v ie w¦ ¦to¦ ¦p ur ch as ing¦ ¦its¦ ¦pote ntial¦ ¦vaccine¦ ¦against¦  - ¦19¦ ¦o nce¦ ¦pr ov en¦ ¦safe¦ ¦and¦ ¦effective¦ .
¦p f iz er¦ ¦vaccine¦ 
¦8¦ 𐋇 ¦january¦ ¦2021¦ ▁-▁ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦prop o ses¦ ¦to¦ ¦p ur ch ase¦ ¦up¦ ¦to¦ ¦3 00¦ ¦million¦ ¦ad di tional¦ ¦doses¦ ¦of¦  - 𐋇¦p f iz er¦ ¦vaccine¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦prop osed¦ ¦to¦  𐋇 ¦me mber¦ 𐋇 ¦states¦ ¦to¦ ¦p ur ch ase¦ ¦an¦ ¦ad di tional¦ ¦2 00¦ ¦million¦ ¦doses¦ ¦of¦ ¦the¦  ¦and¦ 𐋇¦p f iz er¦  - ¦19¦ ¦vaccine¦ ,▁ ¦with¦ ¦the¦ ¦o ption¦ ¦of¦ ¦ac qu ir ing¦ ¦another¦ ¦100¦ ¦million¦ ¦doses¦ .
¦vacc ination¦ ¦medical¦ ¦st ud ent¦ 
¦6¦ 𐋇 ¦january¦ ¦2021¦ ▁-▁ 𐋇 ¦european¦ 𐋇¦c om mi ssion¦ ¦author i ses¦ ¦second¦ ¦safe¦ ¦and¦ ¦effective¦ ¦vaccine¦ ¦against¦  - ¦19¦
𐋇¦the¦ 𐋇¦c om mi ssion¦ ¦has¦ ¦gr an ted¦ ¦a¦ ¦con di tional¦ ¦mark e ting¦ ¦author is ation¦ ¦for¦ ¦the¦ ¦vaccine¦ ¦against¦  - ¦19¦ ¦developed¦ ¦by¦ 𐋇 ¦mod er na¦ ,▁ ¦the¦ ¦second¦ ¦vaccine¦ ¦author i sed¦ ¦in¦ ¦the¦  .
𐋇 ¦vacc ination¦ ¦prot ects¦ ¦people¦ ¦against¦ ¦ser ious¦ ¦and¦ ¦l ife¦ - ¦th re at ening¦ ¦infectious¦ ¦diseases¦ ,▁ ¦such¦ ¦as¦ ¦influenza¦ ▁( ¦flu¦ ),▁ ¦di ph ther ia¦ ,▁ ¦t et an us¦ ,▁ ¦per t us sis¦ ▁( ¦w ho op ing¦ ¦cough¦ ),▁ ¦me as les¦ ,▁ ¦m um ps¦ ,▁ ¦r ub e ll a¦ ▁( 𐋇 ¦g erm an¦ ¦me as les¦ ),▁ ¦m en i ng oc oc c al¦ ¦disease¦ ,▁ ¦inv as ive¦ ¦p ne um oc oc c al¦ ¦disease¦ ¦and¦ ¦po li o¦ .
𐋇 ¦each¦ ¦year¦ ,▁ ¦vacc ination¦ ¦sto ps¦ ¦2¦ .
𐋇¦in¦ ¦the¦ ¦p ast¦ ,▁ ¦many¦ ¦people¦ ¦d ied¦ ¦of¦ ¦diseases¦ ¦that¦ ¦can¦ ¦n ow¦ ¦be¦ ¦prev ented¦ ¦through¦ ¦vacc ination¦ .
𐋇 ¦me as les¦
¦12¦ - ¦18¦ ¦people¦ ▁
𐋇¦the¦ ¦centre¦ ¦d ot¦ ¦rep r es ent¦ ¦one¦ ¦person¦ ¦affected¦ ¦by¦ ¦a¦ ¦disease¦ .
𐋇 ¦vacc ination¦ ¦h el ps¦ ¦prevent¦ ¦the¦ ¦spread¦ ¦of¦ ¦disease¦ ¦in¦ ¦comm un ities¦ .
𐋇 ¦th an ks¦ ¦to¦ ¦vacc ination¦ :
¦s ma ll p o x¦ ¦is¦ ¦n ow¦ ¦e rad ic ated¦ ¦worldwide¦ ;
¦transmission¦ ¦of¦ ¦po li o¦ ¦has¦ ¦e nded¦ ¦in¦ ¦most¦ ¦par ts¦ ¦of¦ ¦the¦ ¦world¦ ,▁ ¦including¦ 𐋇¦e ur ope¦ .
𐋇 ¦vacc ination¦ ¦also¦ ¦prev ents¦ ¦the¦ ¦development¦ ¦of¦ ¦c er tain¦ ¦typ es¦ ¦of¦ ¦pr e¦ - ¦cance ro us¦ ¦gr ow ths¦ ¦and¦ ¦ca nc ers¦ ,▁ ¦for¦ ¦example¦ :
¦vacc in ating¦ ¦against¦ ¦h um an p ap i ll om a¦ ¦virus¦ ▁(  )▁ ¦can¦ ¦help¦ ¦prevent¦ ¦c erv ical¦ ¦and¦ ¦other¦ ¦ca nc ers¦ ¦caused¦ ¦by¦  ¦infection¦ ;
¦vacc in ating¦ ¦against¦ ¦he p at itis¦ 𐋇¦b ¦ ¦can¦ ¦help¦ ¦prevent¦ ¦li ver¦ ¦cance r¦ ¦caused¦ ¦by¦ ¦long¦ - ¦ter m¦ ¦he p at itis¦ 𐋇¦b ¦ ¦infection¦ .
𐋇 ¦vacc ination¦ ¦pr ogra mm es¦ ¦have¦ ¦wid er¦ ¦s oc i et al¦ ¦be ne f i ts¦ .
𐋇 ¦vacc ination¦ ¦is¦ ¦the¦ ¦b est¦ ¦way¦ ¦to¦ ¦ac qu ir e¦ ¦immun ity¦ ¦against¦ ¦vaccine¦ - ¦pre vent able¦ ¦diseases¦ ,▁ ¦as¦ ¦o pp osed¦ ¦to¦ ¦immun ity¦ ¦att a ined¦ ¦by¦ ¦getting¦ ¦the¦ ¦disease¦ .
𐋇 ¦vacc ination¦ ¦prot ects¦ ¦the¦ ¦vaccinated¦ ¦pers ons¦ ¦and¦ ¦those¦ ¦around¦ ¦them¦ ¦who¦ ¦are¦ ¦v ul n er able¦ ¦to¦ ¦the¦ ¦diseases¦ ,▁ ¦reduc ing¦ ¦the¦ ¦risk¦ ¦of¦ ¦diseases¦ ¦sprea ding¦ ¦among¦ ¦family¦ ¦me mbers¦ ,▁ ¦school¦ ¦m ates¦ ¦or¦ ¦coll ea g ues¦ ,▁ ¦f ri ends¦ ,▁ ¦ne i gh bo ur s¦ ¦and¦ ¦other¦ ¦people¦ ¦in¦ ¦the¦ ¦community¦ .
𐋇¦when¦ ¦en ough¦ ¦people¦ ¦in¦ ¦a¦ ¦population¦ ¦are¦ ¦immune¦ ¦to¦ ¦an¦ ¦infectious¦ ¦disease¦ ,▁ ¦the¦ ¦disease¦ ¦is¦ ¦then¦ ¦un li k ely¦ ¦to¦ ¦spread¦ ¦from¦ ¦person¦ ¦to¦ ¦person¦ .
𐋇 ¦community¦ ¦immun ity¦
𐋇 ¦community¦ ¦immun ity¦ ¦occur s¦ ¦when¦ ¦en ough¦ ¦people¦ ¦in¦ ¦a¦ ¦population¦ ¦are¦ ¦immune¦ ¦to¦ ¦an¦ ¦infectious¦ ¦disease¦
𐋇¦in¦ ¦this¦ ¦way¦ ,▁ ¦vaccines¦ ¦ind ir ect ly¦ ¦protect¦ ¦others¦ ¦who¦ ¦are¦ ¦v ul n er able¦ ¦to¦ ¦disease¦ .
𐋇¦it¦ ¦me ans¦ ¦that¦ ¦people¦ ¦who¦ ¦cannot¦ ¦be¦ ¦vaccinated¦ ,▁ ¦for¦ ¦inst ance¦ ¦because¦ ¦they¦ ¦are¦ ¦to o¦ ¦y ou ng¦ ¦or¦ ¦all er g ic¦ ¦to¦ ¦vaccine¦ ¦comp on ents¦ ,▁ ¦be ne f i t¦ ¦from¦ ¦others¦ ¦being¦ ¦vaccinated¦ ,▁ ¦because¦ ¦the¦ ¦disease¦ ¦cannot¦ ¦ ea si ly¦ ¦spread¦ ¦in¦ ¦the¦ ¦community¦ .
𐋇¦for¦ ¦example¦ ,▁ ¦to¦ ¦e ns ure¦ ¦community¦ ¦immun ity¦ ¦against¦ ¦me as les¦ ,▁ ¦public¦ ¦health¦ ¦author ities¦ ¦recomm end¦ ¦that¦ ¦9 5¦ %▁ ¦of¦ ¦the¦ ¦population¦ ¦are¦ ¦vaccinated¦ ¦with¦ ¦two¦ ¦doses¦ ¦of¦ ¦the¦ ¦vaccine¦ ¦against¦ ¦me as les¦ ▁( ¦the¦  ¦vaccine¦ ,▁ ¦which¦ ¦prot ects¦ ¦against¦ ¦me as les¦ ,▁ ¦m um ps¦ ¦and¦ ¦r ub e ll a¦ ).
𐋇¦however¦ ,▁ ¦people¦ ¦cannot¦ ¦r ely¦ ¦on¦ ¦community¦ ¦immun ity¦ ¦for¦ ¦some¦ ¦infectious¦ ¦diseases¦ .
𐋇¦f ur th erm ore¦ ,▁ ¦immun is ation¦ ¦pr ogra mm es¦ ¦help¦ ¦reduce¦ ¦the¦ ¦social¦ ,▁ ¦p s y ch ological¦ ¦and¦ ¦fi na nc ial¦ ¦b ur d ens¦ ¦of¦ ¦disease¦ ¦on¦ ¦people¦ ¦and¦ ¦gover n ments¦ ,▁ ¦reduc ing¦ ¦pre ss ures¦ ¦on¦ ¦healthcare¦ ¦and¦ ¦social¦ ¦care¦ ¦sys tems¦ ¦and¦ ¦e na bl ing¦ ¦people¦ ¦to¦ ¦p u rs ue¦ ¦produc tive¦ ¦activ ities¦ ¦including¦ ¦education¦ ¦and¦ ¦e mploy ment¦ .
𐋇 ¦vacc ination¦ ¦prot ects¦ ¦individuals¦ ¦against¦ ¦diseases¦ ¦that¦ ¦could¦ ¦have¦ ¦ser ious¦ ¦con se qu en ces¦ ¦for¦ ¦their¦ ¦health¦ ,▁ ¦for¦ ¦example¦ :
¦di ph ther ia¦ ¦ki lls¦ ¦1¦ ¦in¦ ¦every¦ ¦10¦ ¦people¦ ¦who¦ ¦get¦ ¦it¦ ,▁ ¦even¦ ¦with¦ ¦treatment¦ ▁( ¦1¦ ) ;
¦al m ost¦ ¦9¦ ¦out¦ ¦of¦ ¦10¦ ¦bab ies¦ ¦ bor n¦ ¦to¦ ¦mo th ers¦ ¦who¦ ¦had¦ ¦r ub e ll a¦ ¦in¦ ¦early¦ ¦pregn a ncy¦ ,▁ ¦will¦ ¦su ff er¦ ¦from¦ ¦co ng en it al¦ ¦r ub e ll a¦ ¦syndrome¦ ▁( ¦with¦ ¦conditions¦ ¦such¦ ¦as¦ ¦d ea f ness¦ ,▁ ¦c at ar ac ts¦ ¦and¦ ¦learning¦ ¦dis ab il ities¦ ) ▁( ¦2¦ ) ;
¦m en i ng oc oc c al¦ ¦disease¦ ¦ki lls¦ ¦1¦ ¦in¦ ¦10¦ ¦people¦ ¦affected¦ ,▁ ¦even¦ ¦with¦ ¦pro mp t¦ ¦diagn o sis¦ ¦and¦ ¦treatment¦ ,▁ ¦while¦ ¦prob le ms¦ ¦including¦ ¦ne ur ological¦ ¦or¦ ¦h earing¦ ¦imp a ir ment¦ ¦and¦ ¦a mp ut ation¦ ¦occur ¦ ¦in¦ ¦up¦ ¦to¦ ¦20¦ %▁ ¦of¦ ¦sur v iv ors¦ ▁( ¦3¦ ) ;▁
¦me as les¦ ¦is¦ ¦high ly¦ ¦conta g ious¦ ¦and¦ ¦3¦ ¦out¦ ¦of¦ ¦10¦ ¦people¦ ¦affected¦ ¦develop ¦ ¦co mpl ications¦ ▁( ¦4¦ ),▁ ¦which¦ ¦can¦ ¦include¦ ¦ ear¦ ¦infection¦ ,▁ ¦di arr ho e a¦ ,▁ ¦pneumonia¦ ¦and¦ ¦en ce ph al itis¦ ▁( ¦inf la mm ation¦ ¦of¦ ¦the¦ ¦b ra in¦ ¦ti ss ue¦ ) ;
¦per t us sis¦ ▁( ¦w ho op ing¦ ¦cough¦ )▁ ¦can¦ ¦be¦ ¦partic ul arly¦ ¦ser ious¦ ¦in¦ ¦in fa nts¦ ,▁ ¦ca us ing¦ ¦cou g hing¦ ¦sp e lls¦ ¦that¦ ¦may¦ ¦r ecu r¦ ¦for¦ ¦up¦ ¦to¦ ¦two¦ ¦mon ths¦ .
𐋇¦this¦ ¦l ist¦ ¦with¦ ¦ex a mp les¦ ¦inclu des¦ ¦diseases¦ ¦for¦ ¦which¦ ¦vaccines¦ ¦are¦ ¦inclu ded¦ ¦in¦ ¦the¦ ¦national¦ ¦immun is ation¦ ¦pr ogra mm es¦ ,▁ ¦and¦ / ¦or¦ ¦are¦ ¦giv en¦ ¦to¦ ¦pers ons¦ ¦consid ered¦ ¦to¦ ¦be¦ ¦at¦ ¦a¦ ¦higher¦ ¦risk¦ ¦of¦ ¦getting¦ ¦the¦ ¦disease¦ .
𐋇 ¦vaccines¦ ¦protect¦ ¦people¦ ¦during¦ ¦different¦ ¦sta ges¦ ¦of¦ ¦l ife¦ .
𐋇 ¦national¦ ¦vacc ination¦ ¦s ch ed u les¦ ¦in¦  /  ¦countries¦ ¦recomm end¦ ¦vaccines¦ ¦at¦ ¦specific¦ ¦a ges¦ ¦and¦ ¦for¦ ¦specific¦ ¦p op ul ations¦ .
𐋇 ¦healthcare¦ ¦pro f es si on als¦
𐋇¦some¦ ¦vaccines¦ ¦are¦ ¦not¦ ¦par t¦ ¦of¦ ¦ro ut ine¦ ¦vacc ination¦ ¦s ch ed u les¦ ¦but¦ ¦are¦ ¦t ar ge ted¦ ¦at¦ ¦specific¦ ¦grou ps¦ .
𐋇 ¦each¦  /  ¦country¦ ¦is¦ ¦resp on si ble¦ ¦for¦ ¦its¦ ¦ own¦ ¦national¦ ¦public¦ ¦health¦ ¦pol ic y¦ ,▁ ¦including¦ ¦its¦ ¦national¦ ¦immun is ation¦ ¦pr ogra m me¦ ¦and¦ ¦vacc ination¦ ¦s ch ed u le¦ .▁ 𐋇 ¦information¦ ¦on¦ ¦the¦ ¦national¦ ¦vacc ination¦ ¦s ch ed u les¦ ¦in¦  /  ¦countries¦ ¦can¦ ¦be¦ ¦found¦ ¦in¦ ¦the¦  𐋇 ¦vaccine¦ 𐋇¦s ch ed ul er¦
𐋇¦there¦ ¦are¦ ¦some¦ ¦di ff er en ces¦ ¦in¦ ¦the¦ ¦way¦ ¦countries¦ ¦or g an ise¦ ¦their¦ ¦vacc ination¦ ¦s ch ed u les¦ ,▁ ¦which¦ ¦are¦ ¦similar¦ ¦but¦ ¦not¦ ¦ident ical¦ ¦in¦ ¦different¦  /  ¦countries¦ .
𐋇 ¦fa ctors¦ ¦d ri ving¦ ¦such¦ ¦di ff er en ces¦ ¦may¦ ¦include¦ ¦the¦ ¦disease¦ ' ¦s¦ ¦b ur d en¦ ,▁ ¦prev al ence¦ ¦of¦ ¦the¦ ¦disease¦ ¦and¦ ¦tr ends¦ ¦in¦ ¦different¦ ¦countries¦ ,▁ ¦the¦ ¦res o ur ces¦ ¦and¦ ¦st ru ct ures¦ ¦of¦ ¦healthcare¦ ¦sys tems¦ ,▁ ¦pol it ical¦ ¦and¦ ¦c ult ural¦ ¦fa ctors¦ ,▁ ¦as¦ ¦well¦ ¦as¦ ¦the¦ ¦re si li ence¦ ¦of¦ ¦the¦ ¦vacc ination¦ ¦pr ogra m me¦ .
𐋇¦the¦ ¦di ff er en ces¦ ¦between¦ ¦vacc ination¦ ¦s ch ed u les¦ ¦do¦ ¦not¦ ¦me an¦ ¦that¦ ¦some¦ ¦are¦ ¦bet ter¦ ¦than¦ ¦others¦ .
𐋇¦the¦ ¦ch ild h ood¦ ¦vacc ination¦ ¦s ch ed u les¦ ¦in¦ ¦all¦  /  ¦countries¦ ¦include¦ ¦the¦ ¦vacc ination¦ ¦against¦ :
¦me as les¦
¦m um ps¦
¦r ub e ll a¦
¦di ph ther ia¦
¦t et an us¦
¦per t us sis¦ ▁( ¦w ho op ing¦ ¦cough¦ )
¦po li om y el itis¦
𐋇 ¦ha e mo ph il us¦ ¦influ en z a e¦ ¦typ e¦ 𐋇¦b ¦
¦human¦ ¦p ap il lo ma vir us¦ ▁( ¦ad ol esc ent¦ / ¦pr e¦ - ¦ad ol esc ent¦ ¦g ir l s¦ ).
𐋇¦the¦ 𐋇 ¦world¦ 𐋇 ¦health¦ 𐋇 ¦organiz ation¦ ▁(  )▁ ¦recomm ends¦ ¦vacc ination¦ ¦against¦ ¦he p at itis¦ 𐋇¦b ¦ ¦as¦ ¦par t¦ ¦of¦ ¦the¦ ¦univers al¦ ¦ch ild h ood¦ ¦vacc ination¦ ¦s ch ed u le¦ ,▁ ¦but¦ ¦some¦  /  ¦countries¦ ¦only¦ ¦vacc in ate¦ ¦children¦ ¦at¦ ¦high¦ ¦risk¦ ¦of¦ ¦infection¦ ¦and¦ ¦ad ul ts¦ ¦in¦ ¦k e y¦ ¦risk¦ ¦grou ps¦ .
𐋇 ¦children¦ ¦in¦ ¦some¦  /  ¦countries¦ ¦are¦ ¦off ered¦ ¦prote ction¦ ¦through¦ ¦vacc ination¦ ¦against¦ :
¦he p at itis¦ 𐋇¦a¦
¦influenza¦
¦inv as ive¦ ¦disease¦ ¦caused¦ ¦by¦ 𐋇 ¦ne i ss er ia¦ ¦m en i ng i ti di s¦
¦inv as ive¦ ¦disease¦ ¦caused¦ ¦by¦ 𐋇 ¦st re pt oc oc c us¦ ¦p ne um on ia e¦
¦ro ta vir us¦
¦t ub erc u lo sis¦
¦vari ce ll a¦
𐋇¦in¦ ¦add ition¦ ,▁ ¦all¦  /  ¦countries¦ ¦have¦ ¦recomm end ations¦ ¦for¦ ¦se as on al¦ ¦influenza¦ ▁( ¦flu¦ )▁ ¦for¦ ¦ ol der¦ ¦people¦ ¦and¦ ¦k e y¦ ¦risk¦ ¦grou ps¦ .
𐋇¦the¦  ¦is¦ ¦ex pl or ing¦ ¦further¦ ¦h arm on is ation¦ ¦of¦ ¦national¦ ¦vacc ination¦ ¦s ch ed u les¦ .▁ 𐋇¦the¦  𐋇 ¦cou nc il¦ ¦issued¦ 𐋇 ¦recomm end ations¦ ¦on¦ ¦7¦ 𐋇 ¦december¦ ¦20 1 8¦
¦on¦ ¦st re ng t he ned¦ ¦co op er ation¦ ¦against¦ ¦vaccine¦ - ¦pre vent able¦ ¦diseases¦ ,▁ ¦which¦ ¦include¦ ¦ex a mi ning¦ ¦the¦ ¦f ea si bility¦ ¦of¦ ¦a¦ ¦c ore¦  ¦vacc ination¦ ¦s ch ed u le¦ .
𐋇¦the¦ ¦ ai m¦ ¦would¦ ¦be¦ ¦to¦ ¦imp ro ve¦ ¦the¦ ¦comp a ti bility¦ ¦of¦ ¦national¦ ¦vacc ination¦ ¦s ch ed u les¦ ¦and¦ ¦pr om ot e¦ ¦e q ual¦ ¦acc ess¦ ¦to¦ ¦vacc in ations¦ ¦across¦ ¦the¦  .
𐋇 ¦each¦  /  ¦country¦ ¦imp le ments¦ ¦its¦ ¦ own¦ ¦immun is ation¦ ¦pr ogra m me¦ .
 /  ¦countries¦ ¦have¦ ¦a ch ie v ed¦ ¦high¦ ¦vacc ination¦ ¦co ver age¦ ¦r ates¦ ¦through¦ ¦mand atory¦ ¦and¦ ¦non¦ - ¦mand atory¦ ¦vacc ination¦ .
𐋇 ¦each¦  /  ¦country¦ ¦dec i des¦ ¦if¦ ¦vacc ination¦ ¦is¦ ¦mand atory¦ ¦or¦ ¦v o lu nt ary¦ ¦in¦ ¦its¦ ¦ter r it ory¦ .
𐋇 ¦information¦ ¦on¦ ¦which¦ ¦countries¦ ¦have¦ ¦mand atory¦ ¦vacc ination¦ ¦can¦ ¦be¦ ¦found¦ ¦in¦ ¦the¦ 𐋇 ¦vaccine¦ 𐋇¦s ch ed ul er¦ .
𐋇¦some¦ ¦people¦ ¦may¦ ¦have¦ ¦m is sed¦ ¦a¦ ¦vacc ination¦ ¦or¦ ¦d id¦ ¦not¦ ¦get¦ ¦the¦ ¦recommended¦ ¦number¦ ¦of¦ ¦doses¦ .
𐋇¦e veryone¦ ¦should¦ ¦ch eck¦ ¦if¦ ¦they¦ ¦have¦ ¦had¦ ¦the¦ ¦na tion ally¦ ¦recommended¦ ¦vacc in ations¦ ,▁ ¦and¦ ¦cons ul t¦ ¦a¦ ¦medical¦ ¦pro f es si on al¦ ¦in¦ ¦case¦ ¦any¦ ¦c at ch¦ - ¦u ps¦ ¦are¦ ¦nee ded¦ .
𐋇¦if¦ ¦a¦ ¦person¦ ¦does¦ ¦not¦ ¦know¦ ¦if¦ ¦they¦ ¦have¦ ¦been¦ ¦vaccinated¦ ¦against¦ ¦a¦ ¦c er tain¦ ¦disease¦ ¦they¦ ¦can¦ ¦us ually¦ ¦get¦ ¦an¦ ¦ext r a¦ ¦d ose¦ ¦without¦ ¦incre as ing¦ ¦the¦ ¦risk¦ ¦of¦ ¦ser ious¦ ¦ side¦ ¦eff ects¦ ▁( ¦1¦ ).
¦me as les¦ ¦vaccine¦
 ¦i 𐋇 st oc k¦
𐋇¦c at ch¦ - ¦up¦ ¦vacc ination¦ ¦pr ogra mm es¦ ¦for¦ ¦specific¦ ¦diseases¦ ¦may¦ ¦be¦ ¦or g an i sed¦ .
𐋇 ¦most¦ ¦vaccines¦ ¦provide¦ ¦l if e lo ng¦ ¦immun ity¦ .
𐋇¦however¦ ,▁ ¦some¦ ¦vaccines¦ ¦provide¦ ¦immun ity¦ ¦that¦ ¦dec rea ses¦ ¦over¦ ¦time¦ ,▁ ¦known¦ ¦as¦ ▁ ‘ ¦w a ning¦ ¦immun ity¦ ’ .▁ 𐋇¦some¦ ¦countries¦ ¦recomm end¦ ¦ bo os ter¦ ¦doses¦ ¦at¦ ¦reg ular¦ ¦int erv als¦ ¦during¦ ¦ad ol esc ence¦ ¦and¦ ¦ad ul th ood¦ ,▁ ¦in¦ ¦order¦ ¦to¦ ¦main tain¦ ¦immun ity¦ ¦over¦ ¦a¦ ¦lo nger¦ ¦period¦ ¦of¦ ¦time¦ ,▁ ¦against¦ ¦for¦ ¦example¦ :
¦di ph ther ia¦
¦t et an us¦
¦per t us sis¦ ▁( ¦w ho op ing¦ ¦cough¦ )
𐋇¦some¦ ¦countries¦ ¦recomm end¦ ¦b oo st ers¦ ¦spec if ically¦ ¦for¦ ¦individuals¦ ¦tra ve lling¦ ¦or¦ ¦at¦ ¦increased¦ ¦risk¦ ¦of¦ ¦being¦ ¦exp osed¦ ¦to¦ ¦the¦ ¦disease¦ .▁
𐋇 ¦healthcare¦ ¦provid ers¦ ¦can¦ ¦provide¦ ¦information¦ ¦on¦ ¦the¦ ¦ bo os ter¦ ¦doses¦ ¦nee ded¦ .
𐋇¦a¦ ¦vaccine¦ ¦may¦ ¦be¦ ¦contr ai nd ic ated¦ ¦for¦ ¦c er tain¦ ¦people¦ ,▁ ¦m ea ning¦ ¦they¦ ¦should¦ ¦not¦ ¦receive¦ ¦it¦ .
𐋇¦a¦ ¦vaccine¦ ¦is¦ ¦contr ai nd ic ated¦ ¦to¦ ¦those¦ ¦all er g ic¦ ¦to¦ ¦any¦ ¦of¦ ¦the¦ ¦vaccine¦ ¦ac tive¦ ¦sub st an ces¦ ¦or¦ ¦i ng re di ents¦ ¦as¦ ¦l is ted¦ ¦in¦ ¦the¦ ¦produc t¦ ¦information¦ .
𐋇¦a¦ ¦h ist ory¦ ¦of¦ ▁' ¦a na ph y la ct ic¦ ' ▁ ¦or¦ ¦other¦ ¦ser ious¦ ¦all er g ic¦ ¦rea ction¦ ¦after¦ ¦rece i ving¦ ¦a¦ ¦vaccine¦ ¦is¦ ¦a¦ ¦contr ai nd ic ation¦ ¦to¦ ¦further¦ ¦doses¦ ¦of¦ ¦that¦ ¦vaccine¦ .
𐋇¦c er tain¦ ¦immune¦ ¦system¦ ¦dis or d ers¦ ▁( ¦ e¦ .
𐋇¦in¦ ¦some¦ ¦cases¦ ,▁ ¦the¦ ¦co mpl et ion¦ ¦of¦ ¦the¦ ¦immun is ations¦ ¦nee ded¦ ¦is¦ ¦recommended¦ ¦pri or¦ ¦to¦ ¦the¦ ¦star t¦ ¦of¦ ¦a¦ ¦treatment¦ ,▁ ¦as¦ ¦during¦ ¦the¦ ¦treatment¦ ¦the¦ ¦pa ti ent¦ ¦may¦ ¦be¦ ¦at¦ ¦higher¦ ¦r is ks¦ ¦of¦ ¦infection¦ .
𐋇¦some¦ ¦vaccines¦ ¦are¦ ¦contr ai nd ic ated¦ ¦during¦ ¦pregn a ncy¦ ,▁ ¦such¦ ¦as¦ ¦me as les¦ ,▁ ¦m um ps¦ ¦and¦ ¦r ub e ll a¦ .
𐋇¦there¦ ¦may¦ ¦be¦ ¦other¦ ¦contr ai nd ications¦ ¦for¦ ¦specific¦ ¦vaccines¦ ,▁ ¦which¦ ¦need¦ ¦disc u ss ing¦ ¦with¦ ¦the¦ ¦healthcare¦ ¦provid er¦ .
𐋇 ¦vaccines¦ ¦are¦ ¦used¦ ¦worldwide¦ ¦as¦ ¦a¦ ¦high ly¦ ¦effective¦ ¦way¦ ¦to¦ ¦protect¦ ¦people¦ ¦from¦ ¦contr ac ting¦ ¦infectious¦ ¦diseases¦ .
𐋇¦the¦ ¦first¦ ¦vaccine¦ ¦was¦ ¦developed¦ ¦in¦ ¦the¦ ¦1 8 th¦ ¦ce nt u ry¦ ¦in¦ ¦the¦ 𐋇 ¦united¦ 𐋇 ¦ki ng d om¦ .
𐋇¦n ow a d ays¦ ,▁ ¦there¦ ¦are¦ ¦vaccines¦ ¦for¦ ¦many¦ ¦diseases¦ .
𐋇¦this¦ ¦v ide o¦ ¦is¦ ¦available¦ ¦in¦ ¦24¦  ¦la ng u a ges¦ .
𐋇 ¦safety¦ ,▁ ¦qu ality¦ ¦and¦ ¦sta nd ards¦
𐋇 ¦before¦ ¦any¦ ¦new¦ ¦vaccine¦ ¦can¦ ¦be¦ ¦used¦ ,▁ ¦it¦ ¦has¦ ¦to¦ ¦under g o¦ ¦r ig o ro us¦ ¦testing¦ .
𐋇¦this¦ ¦ev a lu ation¦ ¦needs¦ ¦to¦ ¦sh ow¦ ¦that¦ ¦a¦ ¦vaccine¦ ’ ¦s¦ ¦be ne f i ts¦ ¦in¦ ¦prot ecting¦ ¦people¦ ¦against¦ ¦diseases¦ ¦are¦ ¦fa r¦ ¦g rea ter¦ ¦than¦ ¦any¦ ¦pote ntial¦ ¦risk¦ .
𐋇 ¦only¦ ¦then¦ ,▁ ¦after¦ ¦appr ov al¦ ,▁ ¦can¦ ¦a¦ ¦vaccine¦ ¦be¦ ¦m an u fa ct ur ed¦ ,▁ ¦mark e ted¦ ¦and¦ ¦used¦ ¦to¦ ¦protect¦ ¦people¦ .
𐋇¦as¦ ¦with¦ ¦any¦ ¦medic ine¦ ,▁ ¦some¦ ¦people¦ ¦may¦ ¦exp eri ence¦ ¦ side¦ ¦eff ects¦ ¦from¦ ¦a¦ ¦vaccine¦ ,▁ ¦but¦ ¦these¦ ¦are¦ ¦us ually¦ ¦mild¦ ¦and¦ ¦sh ort¦ - ¦l iv ed¦ .
𐋇 ¦be ne f i ts¦ ¦of¦ ¦vacc in ating¦
𐋇 ¦vaccines¦ ¦prevent¦ ¦diseases¦ ¦that¦ ¦could¦ ¦o ther w ise¦ ¦cause¦ ¦ser ious¦ ¦health¦ ¦prob le ms¦ ,▁ ¦p erm an ent¦ ¦dis a bility¦ ¦or¦ ¦even¦ ¦death¦ .
𐋇¦for¦ ¦example¦ ,▁ ¦during¦ ¦20 1 8¦ ¦about¦ ¦8 6¦ %▁ ¦of¦ ¦in fa nts¦ ¦worldwide¦ ¦received¦ ¦three¦ ¦doses¦ ¦of¦ ¦the¦ ¦vaccine¦ ¦that¦ ¦prot ects¦ ¦them¦ ¦against¦ ¦di ph ther ia¦ ,▁ ¦t et an us¦ ¦and¦ ¦per t us sis¦ ▁(  ),▁ ¦and¦ ¦8 5¦ %▁ ¦of¦ ¦in fa nts¦ ¦around¦ ¦the¦ ¦world¦ ¦received¦ ¦three¦ ¦doses¦ ¦of¦ ¦po li o¦ ¦vaccine¦ ▁( ¦1¦ ).
𐋇 ¦un li ke¦ ¦a¦ ¦treatment¦ ¦giv en¦ ¦to¦ ¦c ure¦ ¦an¦ ¦illness¦ ,▁ ¦vaccines¦ ¦are¦ ¦us ually¦ ¦giv en¦ ¦to¦ ¦healthy¦ ¦people¦ ¦to¦ ¦prevent¦ ¦them¦ ¦from¦ ¦getting¦ ¦ ill¦ .
𐋇 ¦many¦ ¦infectious¦ ¦diseases¦ ¦are¦ ¦very¦ ¦r are¦ ¦to day¦ ¦th an ks¦ ¦to¦ ¦vacc ination¦ ,▁ ¦so¦ ¦the¦ ¦negative¦ ¦con se qu en ces¦ ¦of¦ ¦these¦ ¦diseases¦ ¦are¦ ¦s om et im es¦ ¦for g ot t en¦ .
𐋇 ¦example¦ :▁ ¦me as les¦
𐋇 ¦me as les¦ ¦had¦ ¦al m ost¦ ¦been¦ ¦e li min ated¦ ¦in¦ ¦many¦ 𐋇 ¦european¦ ¦countries¦ .
𐋇¦however¦ ,▁ ¦since¦ 𐋇 ¦o ct ob er¦ ¦20 1 6¦ ¦a¦ ¦res ur g ence¦ ¦of¦ ¦me as les¦ ¦has¦ ¦been¦ ¦ob s erv ed¦ ¦in¦ ¦the¦  /  ,▁ ¦with¦ ¦out b rea ks¦ ¦in¦ ¦several¦ ¦countries¦ ▁( ¦2¦ ),▁ ¦due¦ ¦to¦ ¦a¦ ¦dec line¦ ¦in¦ ¦vacc ination¦ ¦r ates¦ .
𐋇 ¦me as les¦ ¦can¦ ¦be¦ ¦ser ious¦ ¦or¦ ¦even¦ ¦l ife¦ - ¦th re at ening¦ .
𐋇¦the¦ ¦only¦ ¦prote ction¦ ¦against¦ ¦me as les¦ ¦is¦ ¦vacc ination¦ .
𐋇 ¦example¦ :▁ ¦per t us sis¦
𐋇¦p e rt us sis¦ ▁( ¦w ho op ing¦ ¦cough¦ )▁ ¦is¦ ¦a¦ ¦disease¦ ¦aff ecting¦ ¦the¦ ¦air w ays¦ .
𐋇 ¦co mpl ications¦ ¦can¦ ¦include¦ ¦pneumonia¦ ,▁ ¦en ce ph a lo pa th y¦ ▁( ¦a¦ ¦disease¦ ¦of¦ ¦the¦ ¦b ra in¦ ),▁ ¦se iz ures¦ ¦and¦ ¦even¦ ¦death¦ .
𐋇 ¦vacc ination¦ ¦against¦ ¦per t us sis¦ ¦is¦ ¦par t¦ ¦of¦ ¦national¦ ¦immun is ation¦ ¦pr ogra mm es¦ ¦in¦ ¦the¦  .
𐋇 ¦appr ov al¦ ¦of¦ ¦vaccines¦ ¦in¦ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦un ion¦
𐋇 ¦before¦ ¦a¦ ¦vaccine¦ ¦can¦ ¦be¦ ¦appr oved¦ ¦in¦ ¦the¦  ,▁ ¦it¦ ¦has¦ ¦to¦ ¦under g o¦ ¦r ig o ro us¦ ¦testing¦ ¦by¦ ¦its¦ ¦develop er¦ ¦and¦ ¦then¦ ¦sc ie nt if ic¦ ¦ev a lu ation¦ ¦by¦ ¦regul atory¦ ¦author ities¦ .
𐋇 ¦testing¦ ¦inclu des¦ ¦chec king¦ ¦the¦ ¦vaccine¦ ’ ¦s¦ ¦qu ality¦ :
¦its¦ ¦p ur ity¦ ;
¦its¦ ¦i ng re di ents¦ ,▁ ¦including¦ ¦its¦ ¦in ac tive¦ ¦i ng re di ents¦ ¦or¦ ▁ ‘ ¦ex c ip i ents¦ ’ ;
¦how¦ ¦it¦ ¦is¦ ¦m an u fa ct ur ed¦ .
𐋇 ¦then¦ ¦the¦ ¦vaccine¦ ¦develop er¦ ¦tests¦ ¦the¦ ¦vaccine¦ ’ ¦s¦ ¦eff ects¦ .
𐋇¦this¦ ¦is¦ ¦fo ll owed¦ ¦by¦ ¦a¦ ¦clinical¦ ¦testing¦ ¦pr ogra m me¦ ¦in¦ ¦humans¦ .
𐋇¦this¦ ¦can¦ ¦take¦ ¦around¦ ¦t en¦ ¦years¦ ¦from¦ ¦in it ial¦ ¦con cep t¦ ¦to¦ ¦author is ation¦ .
¦20¦ ▁-▁ ¦100¦ ¦healthy¦ ¦v ol un te ers¦
𐋇 ¦what¦ ¦is¦ ¦chec ked¦ :▁
𐋇 ¦does¦ ¦the¦ ¦vaccine¦ ¦s ee m¦ ¦to¦ ¦work¦ ?
𐋇 ¦are¦ ¦there¦ ¦ser ious¦ ¦ side¦ ¦eff ects¦ ?
𐋇 ¦is¦ ¦the¦ ¦vaccine¦ ¦safe¦ ?
𐋇 ¦at¦ ¦the¦ ¦end¦ ¦of¦ ¦the¦ ¦testing¦ ¦pr ogra m me¦ ,▁ ¦the¦ ¦vaccine¦ ¦develop er¦ ¦sub mi ts¦ ¦the¦ ¦results¦ ¦to¦ ¦the¦ ¦medic ines¦ ¦regul atory¦ ¦author ities¦ ¦in¦ 𐋇¦e ur ope¦ ¦as¦ ¦par t¦ ¦of¦ ¦a¦ ▁ ‘ ¦mark e ting¦ ¦author is ation¦ ’ ▁ ¦app l ic ation¦ .
𐋇¦the¦ ¦regul at ors¦ ¦can¦ ¦only¦ ¦appro ve¦ ¦the¦ ¦vaccine¦ ¦if¦ ¦its¦ ¦sc ie nt if ic¦ ¦ev a lu ation¦ ¦of¦ ¦the¦ ¦tests¦ ¦results¦ ¦sh ow¦ ¦that¦ ¦the¦ ¦vaccine¦ ’ ¦s¦ ¦be ne f i ts¦ ¦are¦ ¦g rea ter¦ ¦than¦ ¦its¦ ¦r is ks¦ .
𐋇 ¦medic ines¦ ¦regul atory¦ ¦author ities¦ ¦can¦ ¦car ry¦ ¦out¦ ¦i ns p ec tions¦ ¦to¦ ¦make¦ ¦sure¦ ¦that¦ ¦the¦ ¦information¦ ¦the¦ ¦vaccine¦ ¦develop er¦ ¦provid es¦ ¦is¦ ¦t ru st w or th y¦ .
𐋇 ¦monit or ing¦ ¦vaccine¦ ¦safety¦ ¦and¦ ¦rep orting¦ ¦ side¦ ¦eff ects¦
𐋇 ¦o nce¦ ¦a¦ ¦vaccine¦ ¦is¦ ¦appr oved¦ ¦for¦ ¦use¦ ,▁  /  ¦national¦ ¦author ities¦ ¦and¦ ¦the¦ 𐋇 ¦european¦ 𐋇 ¦medic ines¦ 𐋇 ¦a ge ncy¦
(  ),▁ ¦contin ually¦ ¦monit or¦ ¦ side¦ ¦eff ects¦ ¦in¦ ¦people¦ ¦who¦ ¦have¦ ¦received¦ ¦the¦ ¦vaccine¦ .
𐋇¦this¦ ¦e ns ures¦ ¦that¦ ¦any¦ ¦possible¦ ¦r is ks¦ ¦are¦ ¦detected¦ ¦and¦ ¦mana ged¦ ¦as¦ ¦so on¦ ¦as¦ ¦possible¦ .
 ¦chec ks¦ ¦new¦ ¦information¦ ¦on¦ ¦the¦ ¦safety¦ ¦of¦ ¦all¦ ¦vaccines¦ ¦available¦ ¦in¦ 𐋇¦e ur ope¦ .▁ 𐋇¦it¦ ¦anal y ses¦ ¦many¦ ¦sour ces¦ ¦of¦ ¦data¦ ,▁ ¦including¦ :
¦rep orts¦ ¦from¦ ¦patients¦ ,▁ ¦par ents¦ ¦and¦ ¦healthcare¦ ¦pro f es si on als¦ ;
¦clinical¦ ¦st u dies¦ ;
¦the¦ ¦medical¦ ¦l it erat ure¦ ;
¦information¦ ¦sh ared¦ ¦by¦ ¦other¦ ¦regul at ors¦ .
 ¦ca re f ul ly¦ ¦ass es ses¦ ¦suspected¦ ¦ side¦ ¦eff ects¦ ¦to¦ ¦det erm ine¦ ¦if¦ ¦there¦ ¦is¦ ¦a¦ ¦ca us al¦ ¦l ink¦ ¦with¦ ¦the¦ ¦vaccine¦ ¦or¦ ¦not¦ .
𐋇¦this¦ ¦v ide o¦ ¦is¦ ¦available¦ ¦in¦ ¦24¦  ¦la ng u a ges¦ .
𐋇¦when¦ ¦nee ded¦ ,▁  ¦and¦ ¦the¦ ¦other¦ 𐋇 ¦european¦ ¦regul at ors¦ ¦take¦ ¦a ction¦ .
𐋇 ¦patients¦ ,▁ ¦healthcare¦ ¦pro f es si on als¦ ¦and¦ ¦ph ar ma ce ut ical¦ ¦comp an ies¦ ¦should¦ ¦report¦ ¦all¦ ¦suspected¦ ¦ side¦ ¦eff ects¦ ¦to¦ ¦their¦ ¦national¦ ¦medic ines¦ ¦regul atory¦ ¦author ity¦ .
𐋇 ¦information¦ ¦on¦ ¦these¦ ¦reported¦ ¦suspected¦ ¦ side¦ ¦eff ects¦ ¦is¦ ¦publ ic ly¦ ¦available¦ ¦on¦ ¦the¦ 𐋇 ¦european¦ ¦d at ab ase¦ ¦of¦ ¦suspected¦ ¦ad ver se¦ ¦drug¦ ¦rea ction¦ ¦rep orts¦ .▁
𐋇¦the¦ ¦proc ess¦ ¦of¦ ¦monit or ing¦ ¦the¦ ¦safety¦ ¦and¦ ¦mana ging¦ ¦the¦ ¦r is ks¦ ¦of¦ ¦medic ines¦ ¦is¦ ¦called¦ ▁ ‘ ¦ph ar ma cov ig il ance¦ ’ .
𐋇 ¦vaccine¦ ¦eff ec ti ve ness¦
𐋇¦a¦ ¦vaccine¦ ' ¦s¦ ¦a bility¦ ¦to¦ ¦prevent¦ ¦a¦ ¦specific¦ ¦disease¦ ¦det erm ines¦ ¦its¦ ¦eff ec ti ve ness¦ .
𐋇¦as¦ ¦with¦ ¦any¦ ¦medic ine¦ ,▁ ¦no¦ ¦vaccine¦ ¦is¦ ¦100¦ %▁ ¦effective¦ ¦in¦ ¦every¦ ¦person¦ ¦vaccinated¦ .
𐋇¦these¦ ¦include¦ :
